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ABSTRACT 
Surgery is standard treatment for early stage endometrial cancer (EC), the most common 
gynaecological malignancy in developed countries. Traditionally, surgery has been performed 
by laparotomy (LT). Comprehensive surgical staging, including pelvic (PLND) and paraaortic 
(PALND) lymph node dissection, is associated with morbidity and possible reduction in 
quality of life. Minimally invasive surgery (MIS) is associated with less morbidity, albeit newer 
MIS techniques, i.e. robot-assisted laparoscopic surgery (RALS), has not been compared with 
LT in a randomised setting. The sentinel lymph node technique is well established in other 
malignancies, however, the experience in EC is limited. The aim of this thesis was to evaluate if 
RALS for PLND and infrarenal PALND (IRPALND) in women with high risk EC is non-
inferior to LT in harvesting lymph nodes, to investigate short- and long-term morbidity as well 
as quality of life. We also wanted to evaluate the sentinel lymph node biopsy concept as a 
diagnostic tool for detecting lymph node metastases (LNM).  
 
In the RASHEC trial, we randomised 120 women with stage I-II EC with high-risk tumour 
features to hysterectomy, bilateral salpingo-oophorectomy, PLND and IRPALND by either 
RALS or LT between 2013 and 2016. Primary endpoint was paraaortic lymph node count. 
Patient-reported outcome (EORTC QLQ-C30 and the endometrial cancer module EN-24, EQ-
5D for generic health status) was assessed before surgery and 12 months after surgery. 
Computed tomography (CT) was performed at baseline, 3 and 12 months after surgery.  
Patient characteristics were evenly distributed between the two groups. In the per protocol 
analysis of 96 patients, difference of means with a 95% confidence interval was within the non-
inferiority margin for infrarenal paraaortic lymph node count (-1.6, 95% CI -5.78 - 2.57). No 
difference in perioperative complications (Clavien-Dindo classification) or readmissions to 
hospital within 30 days after surgery was found. RALS was associated with longer operation time 
(p<0.001) but less total blood loss (p<0.001), shorter hospital stay (p<0.001) and lower health 
care cost (p<0.05) compared to LT. We found no difference in self-reported lower limb 
lymphoedema, occurrence of lymphocysts, serious adverse events or admission to hospital for 
any reason between the two groups 12 months after surgery. Moreover, there was no difference 
in health-related quality of life. 
 
The Sentinel node in High Risk Endometrial Cancer (SHREC- study) is a prospective non-
randomised trial recruiting consecutive patients from two tertiary referral centres in Sweden 
(Lund and Stockholm) between 2014 and 2018 where each woman served as her own control. In 
total 261 patients underwent pelvic sentinel node biopsy followed by completion 
lymphadenectomy of which 257 were analysed. The sentinel lymph node biopsy algorithm 
applied in the SHREC-trial demonstrated a sensitivity for detection of LNM of 100% (95% CI 
92-100) and a negative predictive value of 100% (95% CI 98-100). 
 
 This thesis demonstrates that RALS is non-inferior to LT in harvesting infrarenal 
paraaortic lymph nodes. RALS was associated with shorter hospital stay and lower health care 
cost and there were no evident differences in morbidity or quality of life. Consequently, we find 
RALS to be a valid option for comprehensive surgical staging including IRPALND in high risk 
endometrial cancer. The choice of surgical modality should be made based on surgeons’ and 
patient preference.  
 The sentinel lymph node biopsy algorithm has a satisfactory bilateral mapping rate 
and complete detection of LNM, corroborating previous reports. Gold standard diagnostic 
lymphadenectomy in women EC should therefore be replaced by the less invasive sentinel lymph 
node biopsy. 
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1 
1 INTRODUCTION 
1.1 BACKGROUND  
Endometrial cancer (EC) is the most common gynaecologic malignancy in the industrialised 
world with an estimated 100 000 diagnosed women annually in Europe 1. In Sweden, EC is the 
sixth most common cancer and approximately 1400 new cases are diagnosed every year 2. The 
incidence of EC is rising globally, though a decrease is evident in the Nordic countries 2,3. Risk 
factors include an aging population, obesity, diabetes mellitus, null-parity, late menopause and 
unopposed oestrogen intake 4-8. The median age at diagnosis in Sweden is 69 years. The most 
common histology is endometrioid EC, with a prevalence exceeding 80%. Uncommon histologic 
subtypes of EC include serous and clear cell adenocarcinomas, carcinosarcomas and other 
malignancies. 
The overall relative 5-year survival rate in Sweden is 85% reflecting that most women have early 
stage of disease at diagnosis, Figure 1 9. However, prognosis even in presumed early stage of 
disease differs and depends on various factors including depth of tumour invasion into the 
myometrium, histological grading, tumour size, age, stage of disease and possible lymph node 
involvement 10-12.  
Figure 1. 5-year relative stage specific survival in women with EC diagnosed 2012-16 in Sweden. Stage X 
refers to patients without reported stage. Data publicly available from Swedish Quality Registry of 
Gynecologic Cancer, string Endometrial cancer 13. 
Su
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2 
Staging of EC is surgical and according to the International Federation of Gynaecology and 
Obstetrics (FIGO), latest revised in 2009, see Figure 2 14. Grading is according to World Health 
Organisation classification of tumours into FIGO Grade 1 (43%), Grade 2 (37%) and Grade 3 
(17%). 15. 
 
Figure 2. Staging of endometrial cancer, FIGO 2009. For previous revisions see Appendix 9.1. Illustration by 
Mattias Karlén. 
 
There have been many attempts to predict which women with early stage disease that are 
considered “high-risk” (of recurrence, death of disease and dissemination of disease from 
inception) and whom might benefit from extended comprehensive surgical procedures (pelvic 
and paraaortic lymphadenectomy), adjuvant chemotherapy (ChT) and/or radiotherapy (RT). 
Treatment of “low-risk” disease entails surgical extirpation of the inner genitalia (i.e. total 
hysterectomy and bilateral salpingo-oophorectomy) without adjuvant treatment as distinct from  
  
 
 
  
 
 
 
3 
“high-risk disease” where lymphadenectomy with different extents can be added and adjuvant 
treatment with ChT, RT, chemotherapy followed by RT (CR) or concomitant chemo-radiation 
(CCCR) is recommended.      
There is an international consensus on the definition and treatment of so called “low risk” 
disease. However, opinions differ on the definition and treatment of “high risk” disease confined 
to the uterus. The underlying reasons are multi-factorial and will be discussed. 
 
1.2 THE LYMPHATIC SYSTEM  
The human lymphatic circulatory system accompanies the blood vessels. In contrast to the blood 
circulatory system there is no pump (heart) to help circulate its content. Instead, there is a low-
pressure system with compression from muscles and valves within the lymphatic channels. The 
lymphatic system consists of nodes and lymphoid organs (spleen, thymus, tonsils, vermiform 
appendix and other lymphoid tissue in the gut).  
Three main functions are attributed to the lymphatics. First, to drain plasma (blood without cells 
but with clotting factors) from the interstitium back to the blood stream (the blood capillaries 
loose about three litres of plasma daily to the interstitium). Second, it transports fat 
(chylomicrons) from the bowel to the blood stream. Third, it is part of the immune system 
containing lymph nodes and lymphocytes that cleans the plasma from microbes and tissue debris 
before re-entering the bloodstream. Cancer cells have the ability to enter the lymphatic system.  
Surgical lymph node assessment is performed in all gynaecologic malignancies albeit to different 
extents and anatomic locations. Lymph node metastasis is the most common form of tumour 
dissemination in EC. 
 
1.3 LYMPHADENECTOMY IN ENDOMETRIAL CANCER 
1.3.1 History of lymphadenectomy as part of comprehensive staging 
The first FIGO staging for EC was clinical and implemented in 1950. It consisted of two 
stages where stage I was cancer confined to the uterus and stage II cancer with growth outside 
the uterus 16. In 1987, the American Gynecologic Oncology Group (GOG) published a 
descriptive surgical-pathologic staging study of 621 women with clinical stage I EC. 22% of 
patients had disease outside the uterus upon final histology and an association between tumour 
grade, depth of myometrial invasion (MI) and pelvic lymph node metastases was demonstrated 
(GOG 33) 17. Three risk categories for pelvic lymphatic dissemination was suggested and 
defined as follows;   
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• Low risk (<5% risk of pelvic node metastases) intra-mucosal all grades, grade 1 with 
MI clear-cell and serous histology excluded  
• Moderate risk (5-10% risk of pelvic node metastases) grade 2 with any MI, grade 3 < 
50% MI 
• High risk (>10% risk of pelvic node metastases) was grade 3 with > 66% MI + non-
endometrioid histologies  
 
Risk factors for paraaortic lymphatic dissemination was suggested and defined as follows:  
• Low risk (<5% risk) all except high risk 
• High risk Grade 3 tumours with >66% MI 
As a result, lymphadenectomy was adopted into clinical practice although its efficacy (i.e. 
therapeutic effect of lymphadenectomy, effect of adjuvant RT and/or ChT) had not been proven 
in prospective trials. The revised FIGO staging became surgically based in 1988 16.  The latest 
revision from 2009 also includes defined sub-stages for pelvic and/or paraaortic lymph node 
metastases 18. 
There is no universal definition of “high risk”. There are different opinions and risk 
stratification algorithms, most consist of different combinations of the histological subtype, 
grade of endometrioid histology, depth of MI, cervical stroma invasion, lympho-vascular space 
invasion, age of the patient, size of tumour and in Sweden also DNA-ploidy of the tumour 
cells.  Moreover, different risk group categories before and after surgery exist. The ESMO-
ESGO-ESTRO consensus guidelines from 2015 defines EC with endometrioid histology and 
myometrial invasion >50% or grade 3 endometrioid histology with <50% myometrial invasion 
as an intermediate risk group, women with grade 3 endometrioid histology with >50% 
myometrial invasion or Type 2 histology (clear cell, serous adenocarcinoma or carcinosarcoma) 
as high risk group 19. 
The Swedish National Guidelines on EC, was published for the first time in 2012 and has since 
been revised. The definition of high-risk are as follows; non-endometrioid histology, grade 3 
endometrioid histology, >50% MI, cervical stroma invasion or clinical cervical involvement 9.  
1.3.2 Comprehensive surgical staging and definition of lymphadenectomy 
According to the GOG surgical manual a comprehensive pelvic lymphadenectomy (PLND) is 
defined as removal of the nodal tissue from the distal half of the common iliac arteries, the 
anterior and medial aspect of the proximal half of the external iliac vessels and distal half of the 
obturator fat anterior to the obturator nerve. Paraaortic lymphadenectomy (PALND) is defined  
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as removal of nodal tissue over the distal inferior vena cava from the level of the inferior 
mesenteric artery to the mid right common iliac artery, removal of the nodal tissue between the 
aorta and left ureter from the mid inferior mesenteric artery to the mid left common iliac artery. 
There is no required number of harvested lymph nodes or proportion detected metastases in 
women subjected to lymphadenectomy. In 2008, the Mayo clinic published a study that 
challenged the definition of lymphadenectomy recommended by the GOG. It was demonstrated 
that more than 2/3 of paraaortic lymph node metastases were harboured above the inferior 
mesenteric artery, suggesting that the procedure had to be extended to the renal veins.  
Furthermore, an adequate lymph node count of pelvic lymph nodes was suggested to be 35 and 
17 for PALND. Moreover, they demonstrated that 16% of all patients with lymph node 
metastases had isolated paraaortic lymph node metastases 11. In Europe, there is no 
detailed definition other than “systematic removal” of pelvic and para-aortic nodes up to the 
level of the renal veins and there are no required lymph nodes yield or proportion of detected 
lymph node metastases 19. The Swedish National guidelines has the same definition 9.  
In conclusion, the PLND and PALND in regards to comprehensive surgical staging in 
endometrial cancer is an ill-defined surgical procedure without consensus on exact anatomical 
boundaries and surgical quality. 
1.3.3 Why is lymphadenectomy performed and does it offer a therapeutic benefit? 
Two randomised controlled trials (RCT) have addressed the survival outcome of added pelvic 
lymphadenectomy vs no lymphadenectomy in EC without superior results. Benedetti-Panici et al. 
demonstrated that pelvic lymphadenectomy did not add any overall survival or disease-free 
survival benefit in early stage high risk EC (stage I with MI and endometrioid histology except 
grade 1 <50% MI assessed by per operative frozen section. 514 patients included), though 
lymphadenectomy provided a more accurate staging. With seemingly adequate surgery (lymph 
node count of 30, operation time 180 minutes), the study has been criticised for lacking strict 
criteria for adjuvant treatment 20.  
The multicentre multinational (85 centres, four nations and 1408 patients included) MRC-
ASTEC trial aimed to evaluate the potential therapeutic benefit of systematic pelvic 
lymphadenectomy. Women with presumed early stage EC regardless of risk profile were 
included and randomised to either extirpation of inner genitalia with or without resection of 
obturator and iliac lymphnodes. Furthermore, “sampling” of lymph nodes was allowed. There 
was no difference in survival between the groups.  The study has been criticised for including 
low risk disease, the relatively short operation time (90 minutes), low pelvic lymph node count 
(median 12, 30% <10 lymph nodes) and low proportion lymph node metastases (9%). 
Moreover, 8% of the patients randomised to lymphadenectomy had no lymphadenectomy 21.  
5% of patients in the no lymphadenectomy group had lymph nodes removed with 27% of these 
positive for metastases. Moreover, women with postoperative high or intermediate risk based on  
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uterine factors alone (stage I A and B grade 3, non-endometrioid histology stage IC or IIA 
(FIGO 1988) regardless of positive lymph nodes (stage IIIC)  or not were further randomised to 
receive external beam radiotherapy (EBRT) or not after surgery, which has been criticised since 
these patients at the time were thought to benefit the most of adjuvant radiation therapy 22. 
The Japanese SEPAL study retrospectively compared women with EC confined to the uterus 
subjected to pelvic or pelvic and paraaortic lymphadenectomy 23. The median age of 57 was 
relatively low but median pelvic and paraaortic lymph node count high (pelvic 34 vs 59 and 
paraaortic 0 vs 23).  
There was a significant survival benefit shown in the group of women subjected to extensive 
comprehensive surgical staging although significantly fewer women had chemotherapy in the 
pelvic lymphadenectomy only group (27 vs 47%).  
Chan et al. also conducted a retrospective review of more than 12000 women with endometrioid 
EC and found that women with high risk (and intermediate risk) EC subjected to 
lymphadenectomy had a better survival 24. There is also retrospective data with opposite results25. 
A relatively recent updated Cochrane meta-analysis showed that lymphadenectomy in patients 
with presumed stage I EC did not confer superior survival outcomes 26. 
1.3.4 Perioperative outcomes  
 
One previous trial published 2009 has addressed postoperative complications and was also 
powered to detect potential differences between conventional laparoscopy and laparotomy 
after extirpation of the inner genitalia with pelvic and inframesenteric lymphadenctomy  27. The 
LAP2 trial randomized 2616 women to either laparoscopy or laparotomy (2:1).  98 vs 99% had 
pelvic lymph node assessment with a median node count of 18 vs 17 and 94 vs 97% had 
inframesenteric paraaortic lymph node assessment with a median node count of 7 in both 
arms. The conversion rate from laparoscopy to laparotomy was 25%. There was no difference 
in intraoperative complications but the laparoscopy arm conferred shorter hospital length of 
stay and less use of antibiotics. In regards to postoperative complications measured by the 
United States, National Cancer Institute, Common Terminology Criteria for Adverse Events 
version 2.0 (NCI CTCAE 2.0) at six weeks postsurgery, laparoscopy was associated with fewer 
complications though no obvious differences were evident for specific complications except 
for postoperative ileus28. Nevertheless, this was the landmark study that changed the surgical 
standard of care in EC to minimally invasive surgery (MIS). A recent systematic review of 
surgical modalities in the treatment of EC showed fewer short term postoperative 
complications for robotic surgery compared to laparotomy 29. 
 The potential long-term complication rate and morbidity after PALND and infrarenal paraaortic 
lymphadenectomy (IRPALND) in EC is not known. 
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1.3.5 Lymphatic side effects   
Lymphoedema is a chronic and progressive condition with negative impact on health-related 
quality of life (HRQoL) as well as health care costs 30,31. Surgical resection of pelvic lymph nodes 
can result in lower limb lymphoedema (LLL). LLL can be objectified by measuring the lower 
limbs pre- and post-surgery, or subjectively assessed through different validated questionnaires. 
Self-perceived symptoms of lymphoedema, regardless of objectively measured symptoms or not, 
have been associated with decreased HRQoL and may be used to ascertain treatment effects 32. 
Risk factors associated with LLL include lymphadenectomy, number of harvested pelvic lymph 
nodes, EBRT and obesity. Symptoms can arise year after treatment but are usually apparent after 
3-5 months 33-38.  
Since consensus on standardized measures and definition of LLL are lacking, dispersion of 
reported incidence and prevalence estimates after EC treatment is wide, ranging between 5-38% 
and 0-50% respectively 33-35,39,40.  
After PLND and IRPALND, the proportion of patients with LLL, has been reported to be 18% 
and 37% for robot-assisted surgery and LT respectively 41,42.  
Lymphocele is an organised collection of lymphatic fluid following 
lymphadenectomy. Lymphoceles may exert pressure on adjacent tissue or get infected. It has 
been suggested that MIS is associated with decreased incidence of lymphocele formation after 
PLND 43. Zikan et al. prospectively followed 800 women with gynecologic malignancy that had 
undergone abdominal lymphadenectomy (59% PLND and 41% PLND and PALND) with 
follow up imagining every three months (pelvic and abdominal ultrasound) for two years 44. 38% 
of patients in the cohort had EC and the majority of patients were subjected to laparotomy 
(80%). Moreover 92% were subjected to laparotomy. Proportion of patients with asymptomatic 
lymphocele was 20% of whom a third had symptomatic lymphocele formation.  
There is no evidence supporting the use of abdominal drainage to avoid lymphatic complications 
after lymphadenectomy45-47. Since larger lymphatic channels closer to the cisterna chyli are 
transected during IRPALND, the risk of lymphatic ascites is theoretically higher compared to 
less extensive lymph node dissection (LND). For this reason, abdominal drainage might be of 
clinical value.  
There is a lack of reports describing findings on abdominal computed tomography after 
IRPALND. Therefore, the clinician cannot be guided as to what could be expected.  
Moreover, no randomised trial has compared the frequency of lymphatic findings on 
computed tomography after IRPALND performed either by MIS or laparotomy (LT).   
 
In conclusion, the lymphatic side effects related to the more extensive procedure of 
IRPALND in EC are largely unknown.  
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1.3.6 Health related quality of life and lymphadenectomy  
The LAP2 study evaluated HRQoL after minimally invasive or open surgery with pelvic and 
inframesenteric paraaortic lymphadenectomy with the Functional Assessment Cancer Therapy-
General (FACT-G) questionnaire 48,49. At six-weeks post-surgery, there was a statistically 
significant difference in favour of laparoscopy (“physical functioning”, “body image”, “pain 
inference”, “additional treatment related problems”, “earlier resumption of normal activities”) 
but no domain reached a clinically important difference. At six months’ post-surgery, “body-
image” alone remained significantly in favour of laparoscopy but still did not meet minimally 
important difference. 
Zullo et al. randomised 84 women with stage I EC to either laparoscopy or laparotomy with 
HRQoL as main outcome using the Short Form Health Survey 36 (SF-36) questionnaire 50. All 
women were subjected to PLND and 7% additional non-defined PALND. Laparoscopy 
conferred superior HRQoL outcomes at 1, 3 and 6 months after surgery.  
The HRQoL outcomes associated with infrarenal paraaortic lymphadenectomy are unknown. 
 
1.3.7 Sentinel lymph node biopsy 
The sentinel lymph node (SLN) is the first lymph node adjacent to the lymphatic channels of the 
organ or tissue of interest. The sentinel node biopsy concept (SNBC) is well established in the 
surgical management of several malignancies including breast, melanoma and vulvar cancer, 
offering sufficient information on lymph node status for clinical decision making but with less 
morbidity 51-54. 
In EC SLN mapping was first described in 1996, although the true potential of the technique has 
only been recognized during the last decade 55-57.  A major step forward in simplifying and 
standardising the SNBC in EC was the insight that a peri-tumoural injection could be abandoned 
in favour of cervical injection 58-61. Traditionally, radiotracers (Technetium) with or without 
augmentation of dye have been used for sentinel node biopsy (SNB). Novel tracers such as 
fluorescent dyes (indocyanine green (ICG)) have been demonstrated to be superior 62-67. In 
addition, ICG has the advantage of visualising the afferent lymphatic channels and possibly 
better identifying the most juxta-uterine and “true” sentinel lymph node, see Figure 3.  
It has been suggested that the false negative rate of the SNB concept can be reduced from 15 to 
2% if accompanied by an algorithm including resection of macroscopic suspicious lymph-node 
metastases irrespective of mapping or not and completion LND in case of mapping failure68. A 
Norwegian study with the aim to validate this algorithm used ICG and demonstrated a successful 
bilateral and unilateral mapping in 78 and 96% respectively69.  
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Recent studies suggest that the diagnostic accuracy of SNB in EC may justify its use in clinical 
practice 63,70. Rossi et al prospectively recruited 385 women with early stage EC without prior 
risk-categorisation with a majority being “low-risk” patients (75% MI<50%, 71% grade 1,2)71. 
Each woman served as her own control, with completion LND performed after SNB. The 
bilateral and unilateral mapping was 52 and 86% respectively. The sensitivity of the sentinel 
lymph node specimen was 97% and the negative predictive value close to 100%. 
 
Figure 3. Left; Forceps grasping the sentinel lymph node in the right hemi-pelvis. Right; Forceps grasping the 
sentinel lymph node in the right hemi-pelvis with near infrared display of ICG via Firefly mode®. 
 
Apart from detection rate, the rate of bilateral mapping of sentinel nodes and sensitivity (false 
negative rate included), constitute the most important aspects of the technique. One of the 
potential limitations of the SNB technique in EC is the potential failure to detect isolated 
paraaortic lymph node metastases (LNM) which constitute 15-20% of patients with lymphatic 
dissemination 11,17. No study has yet properly evaluated the technique in this regard.   
However, proportion isolated paraaortic LNM might be lower or potentially non-existent 
following pelvic sentinel node biopsy, since the pelvic lymph node assessment may become more 
precise 72,73. 
Moreover, there is a risk of “empty packet syndrome”, meaning that a macroscopically identified 
SLN do not contain lymphatic tissue upon microscopic evaluation, but the extent of this issue 
has not been explored.  
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Implementation of SNB would change the current surgical management dramatically by omitting 
preoperative risk prediction for lymph node metastases (including imaging to assess myometrial  
infiltration), shorter operation time, lower health care costs and most importantly, potentially less 
perioperative morbidity and lymphatic side effects. There is a lack of scientific support for the 
SNB technique in women with early stage EC with high-risk features only. 
SNB has been included as an option to full lymphadenectomy in the National Comprehensive 
Cancer Network (NCCN, an alliance of American cancer centres) guidelines 74.  
The recommendation stated that sentinel node biopsy mapping may be considered “in select 
patients” but has now been expanded without reservation for patient selection. The European 
Society of Medical Oncology (ESMO) guidelines recommend SLN biopsy as an option in 
intermediate risk stage I EC (defined as grade 3 with <50% MI, or MI>50%)75.  
 
1.4 SURGICAL MODALITIES 
1.4.1 Surgical modalities for pelvic and paraaortic lymphadenectomy 
Laparoscopy was pioneered by Swedish internist Hans-Christian Jacobeus in the early 20th 
century by using a cystoscope 76.  The technique was adopted and developed by gynaecologists. 
In the early 1980’s when the video screen was introduced, laparoscopy gained acceptance and 
became an established surgical treatment modality in the 90’s with the first case-series reported 
on hysterectomy and lymphadenectomy; both pelvic and paraaortic 77-79. Laparoscopic 
hysterectomy with lymphadenectomy for EC has since been evaluated in randomised trials 
against laparotomy. The GOG-LAP2 study showed that laparoscopic hysterectomy with PLND 
and PALND to the inferior mesenteric artery in women with EC conferred the same survival. 
The trial included women with early stage EC of all types, and no evidence in the “high-risk” 
early stage EC population has been provided. 
The LACE trial confirmed the results of the GOG-LAP2 trial and has also shown less health 
care costs in favour of laparoscopy, though lymph node dissection (LND) was not mandatory 
and if performed, only PLND was required (PALND was optional) 80-82. The proportion of 
patients subjected to lymphadenectomy was imbalanced (40 and 58% for laparoscopy and 
laparotomy respectively) and the extent of lymphadenectomy was not defined. Furthermore, the 
low proportion of patients with lymph node metastases (<3.5%) and low number of pelvic 
lymph nodes (10 and 11 for laparoscopy and laparotomy respectively), preclude conclusions 
regarding lymphadenectomy from this trial.   
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Figure 4. Left: the paraaortic field by laparotomy. Right: the paraaortic field by robot-assisted laparoscopic 
surgery. The cephalad border of an inframesenteric paraaortic lymphadenectomy is the IMA. The cephalad 
border of an infrarenal paraaortic lymphadenectomy is the LRV. Abbreviations: LRV, left renal vein; IVC, 
inferior vena cava; DA, descending aorta; IMA, inferior mesenteric artery. 
 
No randomised trial has compared the perioperative outcomes between MIS and laparotomy for 
the more extensive surgical procedure of infrarenal paraaortic lymphadenectomy. Infrarenal 
paraaortic lymphadenectomy as opposed to inframesenteric lymphadenectomy, involves an 
added surgical dissection of 5-7 cm cephalad, making the procedure extremely more demanding 
with the need of much greater area of dissection and surgical skill (see Fig. 4). 
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1.4.2 Robot- assisted laparoscopic surgery 
The United States Food and Drug administration (U.S. FDA) approved Robot-assisted 
laparoscopic surgery (RALS) for gynecologic indications in 2005. The uptake of RALS has been 
dramatic with currently more than 4200 robotic systems worldwide83.  
This tremendous increase has been driven by several factors including the perceived superior 
surgical ergonomics (Fig. 5), the improved dexterity, and presumably a desire to embrace new 
technology. In addition, intense marketing by the only manufacturer has contributed to this 
development.  
Even though RALS seems safe in terms of perioperative morbidity, there is a lack of scientific 
evidence to support the superiority over other surgical modalities from strictly medical aspects84. 
In addition, the investment cost for a robotic system is considerable and the effects on health 
care costs is a major concern.  
 
 
Figure 5. Left: position of surgeon by robot-assisted surgery sitting in the consol. Right: position of surgeon by 
conventional laparoscopy, standing beside the patient. 
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1.5 HEALTH CARE COSTS 
It is stated as part of the Swedish health and Medical Care Act that “publicly financed healthcare 
should be organised to promote cost-effectiveness” (Chapter 4, § 1) 85. There are different 
techniques of evaluating health care economics that are beyond the scope of this thesis, a 
summary is available at the Swedish agency for health technology assessment and assessment of 
social services (SBU)86. In contrary to pharmaceuticals, there is no investigative authority that 
scrutinises technical medical products in Sweden.  
The Health technology assessment centre in Western Sweden Health Care Region evaluated 
RALS in five reports of which one specifically investigated benign gynaecological surgery and 
concluded that RALS could not be regarded as a cost efficient surgical modality 87.  
A review of literature, analyzing 8 surgical procedures  did not find any cost-effective 
benefits of RALS compared to other modalities except for radical prostatectomy88. Since, 
data from the LAPPRO (Laparoscopic Prostatectomy Robot Open) study, a prospective 
non-randomised controlled multi-center Swedish trial with primary objective to evaluate  
urinary continence and erectile function between laparotomy (LT) and RALS conducted 
between 2008-2011, demonstrated that RALS increases cost per procedure by 3837 
United States Dollars as compared to LT, (n=803, 1835 LT and RALS respectively) 89,90.  
1.5.1 Robotic surgery in gynecologic oncology 
 
Reynisson and Persson compared 51 women with cervical cancer subjected to radical 
hysterectomy and pelvic lymphadenectomy by LT with 180 subjected to RALS for. They 
concluded that RALS may confer equal costs after 90 procedures, given that 400 procedures 
are performed per robotic system annually. This translates to a high surgical proficiency and 
volume setting91. Their results were corroborated by Wallin et al92. Another Swedish study 
evaluating the healthcare cost of women with EC subjected to hysterectomy with pelvic 
lymphadenectomy by RALS vs LT (n=40, 48) using the same 7-year depreciation for the 
purchase of a robotic system as Reynisson and Persson and given 350 procedures annually, 
suggested equal costs between modalities93.  
The studies are small and observational why the results must be interpreted very cautiously. 
Furthermore, both studies are based on preconditions that can change, e.g. number of 
procedures, operation time, purchase price of robotic system. In conclusion, the cost efficiency 
of RALS has yet not been decisively demonstrated in a public health care system.  
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1.6 ADJUVANT TREATMENT  
1.6.1 Adjuvant radiotherapy vs no adjuvant radiotherapy 
Adjuvant radiotherapy in the context of both early and advanced stage EC has been explored in 
several randomised trials without superior survival benefits.  
The GOG-99 (included surgical staging according to the GOG surgical manual) and PORTEC-1 
trial (no lymphadenectomy performed) demonstrated that adjuvant pelvic EBRT in early stage 
EC reduced the rate of loco-regional recurrence but did not produce a survival benefit compared 
to no adjuvant treatment after surgery 94,95. 
The PORTEC-2 trial (no lymphadenectomy) demonstrated that vaginal brachy therapy (VBT) 
was as effective as EBRT in reducing the loco-regional recurrence rate with less toxic side effects 
in women with early stage EC without compromising survival 96. Further, the pooled analysis of 
the MRC-ASTEC (some had pelvic lymphadenectomy) and NCIC-CTG EN.5 (no 
lymphadenectomy) study which randomised women with stage I-II intermediate or high risk to 
either pelvic EBRT or no EBRT confirmed the results of the previous trials with no difference 
overall survival (OS) 97.  
1.6.2 Adjuvant chemotherapy or concomitant chemo-radiation vs radiotherapy  
1.6.2.1 Early stage disease 
The Japanese Gynecologic Oncology Group (JGOG) randomised women with stage IC-IIIC 
according to FIGO 1988 staging to either ChT or pelvic EBRT. A subgroup analysis of women 
with high-intermediate risk (stage IC, >70 years, grade 3 endometrioid or stage II or IIIA with 
>50% myometrial invasion) had a significant better survival when allocated to ChT (90 vs 74% 
at 5 years). 96% of patients in this study had PLND and 29% PALND with 12% stage IIIC 
disease in the total group, which suggests an adequate surgical staging. However, patients with 
stage IIIC disease were not included in the subgroup of patients that benefited from ChT 98.  
Maggi et al. allocated women with high risk disease (FIGO 1988 stage IC grade 3, stage II grade 
3 with >50% MI and stage III, pelvic and “lumbo-aortic” lymphadenectomy was optional) to 
either pelvic EBRT or ChT, there was no difference in OS or progression free survival (PFS) 99.  
The more recent GOG 249 study presented at the American Society for Therapeutic Radiology 
and Oncology (ASTRO) randomised women with high or high-intermediate risk stage I-II EC to 
either ChT and VBT or pelvic EBRT, pelvic and paraaortic surgical staging was optional. There 
was no difference in recurrence free survival (RFS) at 5 years and 3-year OS. The proportion of 
patients with stage IIIC disease and subgroup analysis are awaited 100. 
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1.6.2.2 Advanced stage disease 
The GOG-122 study randomised women with stage III and IV (without extra-abdominal 
metastases) EC to either whole abdominal radiotherapy or chemotherapy, patients with residual 
disease <2cm after surgery were included and all patients were surgically staged with 
lymphadenectomy according to the GOG surgical manual 101. 65% of women with stage III had 
stage IIIC and overall, 49% of included women had stage IIIC disease. The results were in 
favour of ChT for both OS and PFS, though subgroup analysis for stage IIIC exclusively was not 
significant.  
Högberg et al. pooled analysis of two RCTs (NSGO/EORTC trial and MaNGO-Iliade trial) 
showed a superior PFS (78 vs 69%) in favour of ChT and EBRT vs EBRT alone for women 
with ill-defined stage I high risk, stage II, IIB stage IIIA-IIIC EC. In subgroup analysis, 
endometrioid histology remained significant but not non-endometrioid. There was no difference 
(but close to significant) in OS (82 vs 75%). Furthermore, there was a significant difference in 
cancer specific survival in favour of ChT + EBRT. Surgical staging was optional (para aortic 
lymph node metastases was an exclusion criteria) and 26% of included patients had pelvic 
lymphadenectomy 102. Moreover, there was no benefit in favour of ChT+EBRT in women 
subjected to LND. 
The PORTEC-3 trial demonstrated that CCCR followed by ChT vs pelvic EBRT only, reduces 
the 5-year RFS (76 vs 69%) but there was no difference in OS. The 5-year OS for patients with 
stage III disease only was better for the ChT+EBRT group (79 vs 70%) though not significantly. 
Unfortunately, the proportion of patients with stage IIIC disease exclusively was not reported 
and only 15% of patients had non-defined lymph node assessment since lymphadenectomy was 
optional 103.  
Results from the GOG 258  trial was presented as abstract in 2017 104. Women with stage 
III/IVA, stage I-II with serous or clear cell histology with positive peritoneal washings were 
randomised to either CCCR followed by ChT or ChT only. Again, surgical staging with 
lymphadenectomy was optional and residual disease of <2cm was allowed. The final results 
showed no difference in RFS between the groups, but less distant recurrences in women 
allocated to ChT only (21 vs 28%, not significant) as opposed to less loco-regional recurrences in 
women allocated to CCCR (vaginal recurrence 3 vs 7%, pelvic and paraaortic recurrence 10 vs 
21%). Proportion patients with stage IIIC, OS and possible subgroup analyses are awaited.   
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1.7 SUMMARY 
2017 marked the 30th anniversary of the GOG-33 study that created the foundation for the 
practice of lymphadenectomy in endometrial cancer. Since, the role of this surgical procedure 
and its extent is still debated and practice differs globally 105. 
Despite several large RCTs, standard of care in women with high risk EC is still subject to 
debate. The main reasons behind the controversies include non-standardised surgery or adjuvant 
treatment, diverse definitions of risk and indications for added lymphadenectomy. Though 
proven non-efficient in multiple large RCTs, the use of adjuvant EBRT continues to be 
recommended in early stage disease. In patients with stage III/IV EC, evidence in favour of 
chemotherapy or concomitant chemo-radiation is growing, although the efficacy in stage IIIC 
disease only remains to be proven. 
The indication for lymph node dissection in EC confined to the uterus is still for 
staging and to “tailor” adjuvant treatment, however, evidence of the efficacy of any adjuvant 
treatment in stage IIIC solely is yet to be provided. Indeed, it has been demonstrated that risk 
factors other than lymph node metastases (age, grade, depth of MI) are independently more 
important in terms of survival106,107. Moreover, risk of recurrence might be high based on uterine 
factors alone in spite of negative lymph node assessment94. The practice of lymphadenectomy 
can thus be disputed. Similarly, pelvic an infrarenal paraaortic lymphadenectomy continues to be 
an ill-defined and strictly diagnostic surgical procedure.  
Based on RCTs, minimally invasive surgery seems safe and has replaced 
laparotomy as the preferable route of surgical access because of less perioperative complications. 
Whether minimally invasive surgery/RALS is safe in IRPALND is not known. Furthermore, the 
side effects and HRQoL related IRPALND is also largely unknown. 
The sentinel lymph node biopsy concept has emerged as a promising alternative to 
full pelvic lymphadenectomy, whether it is a valid diagnostic tool for lymph node assessment in 
women with high-risk early stage endometrial cancer is yet to be established.  
A summary of important and/or influential studies and clinical trials is provided in 
Appendix 9.2.   
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2 OVERALL AIMS OF THE THESIS 
 
The overall aim of this thesis was to evaluate different surgical techniques for lymph 
node assessment, as part of comprehensive staging, in women with high-risk early stage 
endometrial cancer to reduce morbidity without compromising diagnostic accuracy.  
Specific aims of this thesis were: 
1. To investigate if robot-assisted laparoscopic surgery (RALS) was non-inferior to 
laparotomy (LT) in harvesting infrarenal paraaortic lymph nodes (primary 
outcome). To compare number of pelvic node count, perioperative outcomes and 
health care cost as secondary outcomes. 
 
2. To examine serious adverse events, observations on imaging and evaluate self-
reported lower limb lymphoedema at 12 months after surgery (RALS or LT) and 
explore the impact of abdominal drain.  
 
3. To evaluate long-term health-related quality of life related to the extirpation of 
inner genitalia with pelvic and infrarenal paraaortic lymphadenectomy by RALS or 
LT. 
 
4. To explore if the sentinel node biopsy concept with injection of indocyanine 
green in the uterine cervix is a valid diagnostic method in comparison to a full 
pelvic lymphadenectomy in women with with high-risk early stage endometrial 
cancer. 
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3 PARTICIPANTS AND METHODS 
3.1 PARTICIPANTS 
 
3.1.1 Paper I-III 
The Robot-Assisted Surgery in High-risk Endometrial Cancer (RASHEC) study is a 
randomised, open, parallel, single-institution non-inferiority trial performed at the Department of 
Obstetrics and Gynaecology, Karolinska University Hospital, the only tertiary referral centre in 
Stockholm, Sweden. The hypothesis was that RALS is non-inferior in paraaortic lymph node 
yield but with the advantage of offering less perioperative morbidity, shorter hospital stay, less 
lymphatic side effects and better HRQoL.  
Between May 2013 and July 2016, 143 consecutive women were assessed for eligibility. Inclusion 
criteria were: age between 18-75 years, histological confirmed endometrial cancer, presumed 
FIGO stage I or II, preoperative high-risk tumour, performance status 0-1 according to Eastern 
Cooperative Oncology Group (ECOG). Exclusion criteria were: preoperative imaging indicating 
extra-uterine spread, medically unfit for surgery, ongoing anti-tumoural treatment (except 
hormonal therapy e.g. aromatase inhibitors and selective oestrogen receptor modulators, SERM, 
e.g. Tamoxifen), inability to comply to the protocol, unable to understand Swedish. 
Disseminated disease diagnosed during surgery was also an exclusion criteria. In total, 120 
patients were included in the study. 
3.1.2 Paper IV 
The SentineL Node in High Risk Endometrial Cancer (SHREC) study is a prospective single-
arm non-randomised controlled trial performed at two tertiary referral centres in Sweden (Skåne 
University Hospital and Karolinska University Hospital). Consecutive women with high risk 
endometrial cancer were recruited between June 2014 and May 2018. Each woman served as her 
own control. The inclusion criteria were: age 18-85 years, histological confirmed endometrial 
cancer, preoperative high-risk tumour, able to understand and sign an informed consent in 
Swedish language. Exclusion criteria were: performance status ≥3 according to ECOG, previous 
lower limb lymphoedema, evidence of disseminated and/or locally advanced disease, surgical 
contraindication to a laparoscopic approach or lymphadenectomy at the surgeon’s discretion, 
contraindication to minimal invasive surgery at anaesthetist´s discretion, allergy to iodine, known 
liver disease, bleeding disorder or mandatory antithrombotic treatment. In total, 275 patients 
gave informed consent and were included in the study.  
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3.2 METHODS 
3.2.1 Paper I-III 
3.2.1.1 Study design 
The RASHEC study is a randomised, open, parallel, single-institution, non-inferiority trial. 
Randomisation was made after written informed consent at the outpatient clinic, using a 
complete block design with 20 sealed envelopes at a time and the patient drawing a sealed 
envelope. Masking was not performed due to the nature of the treatment. Patients were 
randomly assigned (1:1 ratio) to undergo hysterectomy, bilateral salpingo-oophorectomy 
(SOEB), pelvic (PLND) and infrarenal paraaortic lymph node dissection (IRPALND) through 
laparotomy (LT) or robotic-assisted laparoscopic surgery (RALS).  
 
Figure 6. Study schema for the RASHEC trial. Abbreviations: R, Ratio. 
 
A second randomisation was performed simultaneously to abdominal drain or no abdominal 
drain at time of surgery. The study schema and overall schedule of the RASHEC trial are 
presented in Fig. 6 and 7. 
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Figure 7. Overall study schedule of the RASHEC trial 
 
3.2.1.2 Surgical procedures 
In women randomised to LT, a full midline laparotomy was performed with access to the para-
aortic lymph nodes gained through the Cattell-Braasch manoeuvre, mobilizing the right colon 
and duodenum/pancreas 108. In women randomized to RALS, a double-side docking procedure 
was performed (daVinci Si system, Intuitive Surgical Inc., Sunnyvale, California, USA).  
A passive abdominal drain was placed in women randomised to receive drain. 
3.2.1.2.1 Definition of lymphadenectomy and participating surgeons 
PLND was defined as the dissection and extirpation of all fatty tissue and nodes from half of the 
common iliac vessels cephalad, the external iliac vessels to the circumflex vein caudad and in the 
obturator fossa above the obturator nerve. Although the definition excludes the cephalad part of 
the common iliac vessels, all women underwent complete resection of the common iliac nodes. 
IRPALND was defined as dissection and extirpation of all fatty tissue and nodes up to the left 
renal vein cephalad, the common iliac bifurcation caudad, performed interaortocaval, paraaortal 
and paracaval. The lateral paraaortic border being the left gonadal vein and the paracaval lateral 
border the ureter. The depth of the dissection inter-aortocavally was the anterior spinous 
ligament and the iliopsoas muscle paraaortic and paracavally. Complete retro-caval and retro-
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aortic dissection was optional. Five surgical gynecologic oncologists performed the laparotomies 
and one all RALS. All surgeons were certified subspecialists in Gynecologic Oncology by the 
Swedish Society of Obstetrics and Gynecology (SFOG).  
3.2.1.3 Imaging 
Computed tomography (CT) scans of the abdomen was performed routinely at baseline (pre-
surgery) and at three and 12 months after surgery as per study-protocol. All CT scans were 
performed using commercially available multidetector CT after administration of intravenous 
contrast agent. The assessment protocol included: presence of suspicious lymph nodes, 
lymphocysts, ascites, recurrence and other potential abnormal findings. All CT-scans were re-
reviewed by a specialized radiologist with more than 10 years’ experience in diagnostic 
oncological imaging. 
3.2.1.4 Long term serious adverse events and admissions to hospital for any reason 
Medical charts were reviewed for admissions and long-term adverse events for any reason.  
Clavien-Dindo classification grade ≥ 3 was considered a serious adverse event, which 
corresponds to a minimum requirement of surgical, endoscopic or radiological intervention 
(grade 3) up to death of a patient (grade 5) 109. The variables were assessed at day 31-365 post-
surgery and per patient. 
3.2.1.5 Self-reported lower limb lymphoedema 
In accordance with the recommendations of quality of life (QoL) and patient reported outcomes 
from the Gynecologic Cancer Intergroup (GCIG), we used two questions from the QLQ-EN24 
questionnaire to capture symptoms of lower limb lymphoedema (LLL) i.e. “Have you had swelling 
in one or both legs” and “Have you felt heaviness in one or both legs” with answers from “not at all”, “a 
little”, “quite a bit” and “very much” 110.  The association of previously reported and exploratory 
predictors of self-reported LLL were assessed. The agreement between lymphatic “side-effects” 
objectively measured by CT at 12 months and self-reported LLL was assessed.   
3.2.1.6 Questionnaires 
 
To assess patient-reported outcomes and health-related quality of life, three validated 
questionnaires (EORTC QLQ-C30, QLQ-EN24 and EQ-5D-3L) were used and distributed to 
the patients before surgery (baseline), at three and 12 months after surgery.  The questionnaires 
were either given to the patient at the clinic or sent home by conventional mail together with 
prepaid return envelopes.  
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The European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30 (EORTC QLQ-C30) includes overall quality of life (global health status), 
five functional scales (physical; role; emotional; cognitive; and social), three symptom scales 
(fatigue; nausea/vomiting; and pain), and six single items (dyspnoea; insomnia; appetite loss; 
constipation; diarrhoea and financial difficulties). The EORTC QLQ-C30 is considered to have 
good psychometric qualities and has been validated in Swedish 111,112.   
 
The EORTC endometrial cancer supplementary module (QLQ-EN24) 111,113 includes three 
functional scales (sexual interest; sexual activity; sexual enjoyment), five symptom scales 
(lymphoedema; urological; gastrointestinal; poor body image; vaginal) and five single items 
(pain in back and pelvis; tingling/numbness; muscular pain; hair loss; taste change).  
 
Figure 8. Overview of the main questionnaires in the RASHEC trial 
 
 
The QLQ-EN24 has also been validated in two international studies showing good 
psychometric qualities, the Swedish version of the questionnaire was part of the first validation 
study 113,114. The response format for both questionnaires is on a four-point scale, from 1 (Not 
at all) to 4 (Very much), except for two items in EORTC QLQ-C30 which are scored on a 
seven-point scale. A high score on the functional scales and global quality of life represents a 
high level of functioning and quality of life. A high score on the symptom scales/items 
represents a high level of symptoms. An overview of the EORTC questionnaires are presented 
in Fig. 8. 
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The EQ-5D-3L questionnaire, introduced in 1990 from the EuroQoL group, measures non-
disease specific health status 115. It encompasses five questions regarding “anxiety and 
depression”, “pain/discomfort”, “usual activity”, “self-care” and “mobility” with three levels 
of answers; “no problems”, “some problems” and “extreme problems”. In the additional 
visual analogue scale (VAS), patients are asked to report their global health state in a scale from 
0-100. The Swedish version of the questionnaire has been validated 116. 
 
3.2.1.7 Cost per patient 
Healthcare costs related to LT or RALS were calculated using the regional case-costing system 
(cost per patient, CPP). The total cost included all associated costs of ward care (e.g. staff, 
radiology, laboratory, medication) as well as costs related to activities performed in the operation 
theatre (all surgical instruments and draping included), postoperative care and pharmaceuticals. 
To calculate the additional cost specific for robot-assisted surgery, a 7-year depreciation for the 
robotic system and an annual caseload of 350 procedures/system were assumed.  
We converted Swedish Crowns (SEK) to United States dollars (USD) using the 2013 currency 
rate (US $1 = 6.51 SEK) and SEK to Euro (€) using the 2013 currency rate (€ 1= 8.33 SEK). 
Costs related to complications within 30 days after surgery were included in the analyses. 
 
3.2.2 Paper IV 
3.2.2.1 Study design 
The SHREC study is a prospective single-arm non-randomised controlled trial.    
3.2.2.2 Primary outcome 
Primary outcome measure was the diagnostic accuracy of our proposed sentinel lymph node 
biopsy algorithm as compared to gold standard LND for the detection of pelvic lymph node 
metastases. The diagnostic accuracy was defined by the sensitivity and negative predictive. 
Moreover, the sensitivity of the sentinel lymph node specimen and the NPV of successfully 
mapped women only.  
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3.2.2.3 The sentinel lymph node procedure 
Enrolled women were scheduled for hysterectomy, bilateral salpingoophorectomy, pelvic 
sentinel lymph node biopsy and full pelvic and infrarenal paraaortic lymphadenectomy. A full 
pelvic lymphadenectomy only was permitted if indicated, e.g. advanced age or severe 
comorbidity. The surgeries were performed by robot-assisted laparoscopic surgery (RALS) using 
a da Vinci® Si or Xi Surgical System (Intuitive Surgical, Sunnyvale, CA, USA).  
  
Before entering the abdomen, indocyanine green (2.5mg/mL) was injected in the submucosa and 
stroma of the cervix uteri at 2-4-8 and 10 o’clock. At each injection site, 0.25mL (0.625 mg ICG) 
was administered, with a total dose of 2.5 mg (Fig. 9). After the injection, a fornix presenter was 
placed (without any intracervical device) as per usual. 
 
 
Figure 9. Injection of ICG in the uterine cervix. A. Syringe with diluted ICG. B. 
Uterine cervix grasped with Schröder forceps, yellow tube is the urinary 
catheter, injection of ICG in uterine cervix at 2 o’clock. 
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Figure 10. Transperitoneal display of 
florescent ICG in the upper para-
cervical pathways with fire-fly camera 
mode. Top, overview. Middle, right 
side. Bottom, left side. A; Posterior 
uterine fundus. B; Broad ligament. C; 
Uterine Cervix. D; Ovary. E; Fallopian 
tube. 
After entering the abdomen, 
fluorescence imaging with 
FireFly® Mode was used to 
identify the upper paracervical 
lymphatic pathway (UPP) along 
the uterine artery to the external 
and obturator nodes, continuing 
lateral to the common iliac artery 
to the inframesenteric paraaortic 
nodes. The lower paracervical 
pathway (LPP) medial to the 
internal iliac artery to the internal 
iliac and presacral nodes and 
continuing medial to the 
common iliac artery to the 
inframesenteric paraaortic area.  
The display of ICG (Fig. 10) in 
the respective pathways was 
evaluated a minimum of 10 
minutes after the injection of 
ICG, first trans-peritoneal and if 
not seen, after opening of the 
retroperitoneal pelvic avascular 
planes starting with the pre-
sacral, para-vesical and para-
rectal planes leaving the 
lymphatics intact with the aid of 
switching between white light 
and FireFly Mode. A second 
ipsilateral injection (0,25mL 
ICG) at 3 and 9 o’clock was 
made if no sentinel pathway 
could be visualised. 
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The pelvic sentinel lymph nodes (SLN) were defined as the juxta-uterine ICG positive node with 
an afferent ICG positive lymphatic channel in each of the UPP and LPP respectively on each 
pelvic side with the possibility of parallel lymphatics in the UPP to the external and obturator 
areas (Fig. 11). These SLN were defined as SLN type 1.  
 
 
Figure 11. The afferent lymphatic pathways draining the uterine corpus. Abbreviations: 
LPP, lower paracervical pathway; UPP, upper paracervical pathway; IPP, infundibulo-
pelvic pathway. Illustration by Mattias Karlén. 
 
In case of a ICG positive lymph vessel where no nodes were ICG positive in that pathway, the 
node where the ICG positive lymphatic channel ends was defined as SLN type 2. Nodes 
macroscopically suspect of metastatic disease was defined as SLN Macro regardless of ICG 
uptake. After surgical resection of the sentinel lymph nodes, a completion compartmental 
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lymphadenectomy was performed with a rigorous labelling protocol and sent to the pathology 
department. 
3.2.2.4 Pelvic sentinel lymph node algorithm 
The algorithm comprised assessment of the UPP and LPP in both hemi-pelvises together with 
resection of all macroscopic suspicious lymph nodes regardless of mapping success or not. 
Reinjection of ICG tracer in the uterine cervix was allowed in case of uni- or bilateral non-
display.  
3.2.2.5 Histopathological assessment  
Examination and evaluation of SLNs was performed by a restricted number of pathologists 
under the supervision of a gynecologic reference pathologist according to a standardized 
protocol. All macroscopically identified sentinel lymphoid tissue was embedded and bisected if 
the minimum thickness exceeded 3 mm. Ultrastaging using hematoxylin and eosin staining 
(H&E) was performed in five sections at three different levels, 200 µm apart, if the maximum 
diameter of the sentinel node tissue exceeded 1 mm. Immunohistochemistry (IHC) with staining 
for pan-cytokeratin and cytokeratin MNF 116 was performed.  
Non-SLNs with a thickness less than 3 mm were embedded entirely and for nodes exceeding 3 
mm at least half the node was embedded. Non-SLNs were stained for H&E but was not 
subjected to IHC. 
The pathologists were not blinded to the results of SLNs and non SLNs when performing their 
assessment.   
3.2.2.5.1 Definition of lymph node metastases 
For the definition of lymph node metastases we used the classification is according to American 
Joint Committee on Cancer (AJCC) staging for axillary nodes in breast cancer117. 
• Macro-metastases = tumour greater than 2.0 mm in diameter. 
• Micro-metastases = tumour cell aggregates between 0.2 and 2.0 mm in diameter. 
• Isolated tumour cells =individual tumour cells or aggregates that are less than 0.2mm in 
diameter, usually detected by immunohistochemistry. 
• Tumour absent – no tumour cells identified in H&E (or immunohistochemically, if 
applicable) stained sections. 
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3.3 STATISTICAL PLAN AND ANALYSIS 
3.3.1 Paper I-III 
3.3.1.1 Primary outcome 
Statistical assumptions of the primary outcome (number of infrarenal paraaortic lymph nodes) 
were based on our previous experience that demonstrated a mean paraaortic lymph node yield of 
16.4 lymph nodes for laparotomy, combined with benchmarking data from the Mayo clinic 
demonstrating a mean paraaortic lymph node yield of 17.4 with a standard deviation (SD) of 8 11. 
Minimum node count for systematic paraaortic lymphadenectomy has been reported as 10 118, 
why a non-inferiority margin of 6 lymph nodes was chosen. A sample size of 47 patients in each 
group was rendered with a power of 95% and a one-sided alfa of 0.025. With an expected 20% 
dropout rate, 120 patients needed to be recruited. For analysis of mean difference, significance 
and confidence intervals in primary outcome, independent two-sided t-test was performed and 
the assumptions for the test was fulfilled. Mann Whitney U test was performed for unevenly 
distributed data. Frequency distributions between categorical variables were compared with 
Fisher’s exact test. All P-values were two-sided and a P-value less than 0.05 was considered 
significant. All analysis is based on the per protocol (PP) group where complete staging was 
performed, except for proportion of patients with lymph node metastasis were the intention-to-
treat group was analysed separately. Descriptive statistics were presented as median and range 
(minimum-maximum) or mean ±SD.  
3.3.1.2 Secondary outcomes 
The effect of known and potential risk factors on self-reported lymphoedema at 12-months after 
surgery was estimated and tested using linear regression models. Statistically significant (p<0.05) 
factors identified from the univariate analyses were all included in a final multivariate model. 
Results from these models are presented as mean differences together with 95% confidence 
intervals. Results from the multivariate analyses were confirmed by non-parametric bootstrap 
methods with 10.000 replicates 119. Reported p-values refer to Wald tests. Agreement between 
self-reported lymphoedema (dichotomized to “not at all” and “any extent”) at 12 months after 
surgery and lymphocele formation or ascites assessed by computed tomography, was evaluated 
using kappa statistics, a kappa (strength of agreement) of <0.20 was considered poor, 0.21-0.40 
fair, 0.41-0.60 moderate, 0.61-0.80 good and 0.81-1.00 very good 120. The proportion of women 
with any extent of reported lymphoedema before and at 12 months after surgery, as women who 
were admitted to hospital or experienced a serious adverse event between day 31-365 after 
surgery, were assessed and compared with Fisher’s exact test.  Data for the EORTC QLQ-
C30/QLQ-EN24 was scored according to the EORTC QLQ-C30 manual, missing values were 
treated accordingly 121. All scales were linearly transformed to range from 0 to 100. In the 
interpretation of the EORTC QLQ-C30/QLQ-EN24 scores a difference of >5 points were  
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considered clinically important for the patients, i.e. could be experienced by them 122. Differences 
of 5-9 points were considered small, those of 10-19 moderate, and >20 large 123. The effect of 
surgical modality on each of the scale scores at the 12-month assessment was evaluated using 
linear regression models including type of operation (laparotomy, robot assisted laparoscopic 
surgery) and baseline scale scores. Results from these models are presented as mean differences 
together with 95% confidence intervals. P-values from these models refer to Wald tests. A P-
value of <0.05 was considered significant. No adjustment was made for multiple comparisons.  
For the EuroQoL EQ-5D-3L answers were dichotomised to “not at all” or “any extent” and 
comparisons at the different assessment time points were made without adjustment for baseline, 
proportions were compared with Fisher’s exact test. For the EuroQol visual analogue scale 
(VAS), the median score at the assessment points by surgical modality was compared with Mann 
U Whitney test. 
3.3.2 Paper IV 
The analysis of sensitivity, false negative rates and negative predictive value was evaluated per 
patient with regards to the SNB algorithm and in mapped women only. As at least a full pelvic 
lymphadenectomy was performed in addition to the separate removal and analysis of SLNs. 
Each woman served as her own control in terms of overall pelvic node positivity. All women 
who underwent the planned procedure according to protocol were included in the analyses of 
primary outcome. All women injected with ICG tracer were included in the safety assessment. 
 As it has the highest probability of early termination under the efficacy hypothesis, 
the preferred statistical method was the Fleming two stage design for determination of sample 
size, interim analyses and decision to stop accrual based on sensitivity 124. The null hypothesis 
that sensitivity was 85% was tested against a one-sided alternative with a desired sensitivity of at 
least 92.5%. The interim analysis was planned after 50 ICG mapped (at least one SLN-ICG) 
women with pelvic LNM were identified. This was continuously monitored and enrolment was 
stopped and interim analyses performed accordingly. Preliminary, this would require 
approximately 250 enrolled patients with an estimated 20% pelvic LNM rate. Enrolled women 
awaiting final histology when accrual was stopped were included in the study.  
 If the number of patients with pelvic LNM correctly identified by at least one ICG 
mapped SLN was equal to or lower than 43 the study would be stopped for futility. If the 
number of patients identified were equal to or higher than 48 the hypothesis of inefficacy could 
be rejected with no further enrolment. If the total number of success was between the lower and 
the upper cut-off points, the trial would continue by including an additional 69 patients with 
pelvic LNM. The hypothesis of inefficacy would be rejected if 107 or more patients with pelvic 
LNM were correctly identified by an ICG mapped SLN. This design yielded a type 1 error of 
0.05 and a power of 0.8 when the true sensitivity is 92.5%. Exact 95% confidence intervals and 
sensitivity, false negative rates and negative predictive values are reported and estimated by 
proportions. Descriptive data was presented with numbers and percentage or median and range 
(minimum-maximum).
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4 RESULTS 
 
4.1 PAPER I-II 
Between May 2013 and July 2016, 143 consecutive patients were assessed for eligibility to the 
RASHEC trial and 120 women were randomised, RALS (n=60) or LT (n=60).  
Figure 12. Consort Flow Diagram RASHEC trial. Accrual between May 2013 through July 2016.  
As shown in Figure 12, four women in the RALS group and three in the LT group did not 
undergo the allocated procedure, leaving 113 patients in the intention-to treat group. Of the 56 
patients in the RALS group, the procedure was aborted in 8 women (14.3%) due to gross lymph 
node metastases, technical difficulties gaining access to the paraaortic area or conversion to LT. 
Assessed for eligibility (n=143) Excluded (n=23)
Not meeting inclusion criteria (n=14)
Declined to participate (n=8)
Other reason (n=1)
Randomised
Allocated to Laparotomy (n=60)
Received allocated intervention (n=57)
Did not receive allocated intervention (n=3)
1 Withdrawal
1 Comorbidity
1 Stage IV
Allocated to Robotic Surgery (n=60)
Received allocated intervention (n=56)
Did not receive allocated intervention (n=4)
1 Low risk histology 
2 Comorbidity
1 Surgery aborted because of sick sinus syndrome
upon induction of anesthesia
Planned procedure not performed (n=7)
2 Macroscopic lymph node metastases, 
systematic lymphadenectomy aborted
1 No access to the paraaortic region, only 
pelvic lymphadenectomy performed
1 Too high surgical risk, lymphadenectomy 
aborted
3 Stage IV macroscopic per-operatively
Lost to follow-up (n=1) 
1 Withdrawal after surgery
Excluded from analysis (n=1)
1 Other primary cancer upon final pathology
review
Planned procedure not performed (n=8)
3 Macroscopic lymph node metastases,
systematic lymphadenectomy aborted
4 No access to the paraaortic region, only 
pelvic lymphadenectomy performed
1 Conversion to laparotomy due to technical   
difficulties          
Analysed (n=48) Analysed (n=48)
ALLOCATION
ANALYSES
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Table 1. Baseline demographics, clinical and pre-operative tumour 
characteristics of endometrial cancer patients by surgical technique, per 
protocol. 
 
 
 
 
Characteristic 
Laparotomy 
(n=48) 
Robotic surgery 
(n=48) 
Age, years 
   Median 
   Range 
 
67 
52-75 
 
66 
39-75 
BMI kg/m2 
   Median 
   Range 
 
27 
18-43 
 
26 
17-38 
ECOG performance status, no. (%) 
   0 
   1  
 
47 (98) 
1 (2) 
 
45 (94) 
3 (6) 
Comorbidity, no. (%) 
   Diabetes 
   Hypertension 
   Cardiovascular disease 
   Asthma 
   Previous malignancy* 
 
4 (8) 
18 (38) 
5 (10) 
3 (6) 
8 (7) 
 
2 (4) 
21 (44) 
4 (8) 
2 (4) 
4 (8) 
Marital status, no. (%) 
   Married or living with a partner 
   Has a partner but lives alone 
   Widow 
   Single 
 
31 (65) 
3 (6) 
1 (2) 
13 (27) 
 
31 (65) 
3 (6) 
1 (2) 
13 (27) 
Level of education, no. (%) 
   Elementary school 
   Secondary school 
   College/University 
 
13 (27) 
22 (46) 
13 (27) 
 
8 (17) 
19 (40) 
21 (44) 
Employment status, no. (%) 
   Student 
   Unemployed 
   Employed 
   Retired 
 
0 
0 
17 (35) 
31 (65) 
 
0 
1 (1) 
17 (35) 
30 (63) 
Cigarette smoking 
   Current smoker 
   Former smoker 
   Never smoker 
 
9 (19) 
15 (31) 
24 (50) 
 
3 (4) 
14 (29) 
31 (65) 
Clinical FIGO stage, no. (%) 
   I 
   II 
 
43 (90) 
5 (10) 
 
42 (88) 
6 (13) 
Pre-operative histology, no. (%) 
   Endometrioid 
       FIGO Grade 1 
       FIGO Grade 2 
       FIGO Grade 3 
    
   Non-Endometrioid 
     Serous  
     Clear cell 
     Carcinosarcoma 
     Other 
 
17 (38) 
0 
8 (17) 
9 (20) 
 
31 (65) 
20 (42) 
3 (6) 
5 (10) 
3 (6) 
 
21 (44) 
1 (2) 
7 (15) 
11 (24) 
 
27 (56) 
23 (48) 
4 (8) 
2 (4) 
0 
Pre-operative  
myometrial invasion4, no (%)                                 
      <50% 
      ≥50% 
 
33 (69) 
15 (31) 
 
 
29 (60) 
19 (40) 
Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group;  
FIGO, International Federation of Gynecology and Obstetrics.  
Range (minimum-maximum). * Ten patients with previous breast cancer, one with previous 
colorectal cancer and one with previous malignant melanoma.1Mann Whitney U test. 
2Fisher’s exact test. 3Students t-test.4Myometrial invasion estimated by magnetic 
resonance imaging or ultrasound. 
  
 
 
  
 
 
 
33 
In the LT group, the planned surgery was aborted per-operatively in 7 of 57 women (12.3%) due 
to gross lymph node metastasis, technical difficulties or disseminated disease (Fig. 12). One 
additional patient withdrew consent after surgery and the final pathology review of one patient 
revealed another primary cancer. 96 patients, evenly distributed between the surgery groups, were 
included in the per protocol analysis. A gynecologic expert pathologist reviewed 71% of the 
specimens in the LT group and 75% in the RALS group. 96 patients, evenly distributed between 
the surgery groups, were included in the per protocol analysis. Demographics, clinical and pre-
operative tumour characteristics were well balanced between groups (Table 1).   
4.1.1 Lymph nodes yield and metastases  
There was no difference in mean number of para-aortic lymph nodes harvested up to the renal 
vein between RALS (20±9.6) and LT (22±11, p=0.45), see Table 2. Difference of means with a 
95% confidence interval was within the non-inferiority margin for paraaortic lymph node count 
(-1.6, 95% CI -5.78 - 2.57) (Fig.13). Pelvic lymph node count was lower in the RALS vs LT 
group (22±8 vs. 28±10 p<0.001). 
 
 
Figure 13. Difference of means with 95% Confidence Interval in harvested 
paraaortic lymph nodes between robotic surgery and laparotomy 
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In both the intention-to treat and per protocol analyses, the prevalence of lymph node metastasis 
was higher, albeit not significant, in the RALS group compared to LT (21% vs. 14% and 19% vs. 
13% respectively).  
If metastases were present, 47% were harboured in both the pelvis and paraaortic region, 33% 
only in the pelvis and 20% only in the paraaortic region, i.e. 3% of all women in the per protocol 
analysis had isolated paraaortic lymph node metastases. Paraaortic lymph node metastases were 
located above the inferior mesenteric artery (IMA) in 80% of the cases. 
 
Table 2. Mean (±SD) number of lymph nodes harvested through systematic 
lymphadenectomy and the prevalence of lymph node metastases, by surgical modality. 
 
4.1.2 Peri- and postoperative outcomes and imaging 
Peri- and postoperative short and long-term outcomes are shown in Table 3. There were no 
differences between the groups other than longer operation time, less total blood loss and 
shorter hospital stay in the RALS group. Moreover, there was no difference in lymphocyst 
formation although a non-significant difference was found in the anatomical distribution of 
lymphocysts, with a higher prevalence of paraaortic and lower prevalence of pelvic lymphocysts 
in the RALS group, though not significant (Table 3, Fig. 14).  
	
	
	
 
 
 
 
Lymph node region 
Laparotomy 
(n=48) 
Robotic surgery 
(n=48) 
 
P-value 
 Mean (SD) Mean (SD)  
Paraaortic region 
   Above IMA2 
   Below IMA3 
 
22 (11) 
13 (7) 
10 (5) 
 
20 (10) 
12 (7) 
9 (5) 
 
0.451 
0.761 
0.521 
 
Pelvic region 
   Left pelvis 
   Right pelvis 
    
28 (10) 
14 (6) 
14 (6) 
22 (8) 
10 (5) 
12 (5) 
 
<0.0011 
<0.051 
<0.051 
 
Paraaortic and pelvic region 50 (19) 42 (16) <0.0011 
Lymph node metastases, n (%) 6 (13) 9 (19) 0.584 
Lymph node metastases ITT5, n (%) 
    
8 (14) 
 
12 (21) 
 
0.334 
 
Abbreviations: IMA, Inferior mesenteric artery; SD, standard deviation.  
1Students t-test. 2Above IMA is defined as the region between the renal vein and inferior mesenteric artery.3Below 
IMA is defined as the region between iliac bifurcation to the inferior mesenteric artery.4Fisher’s exact test. 
5Intention to treat analysis. 
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None of the women had symptomatic lymphocysts requiring intervention.  
In total, 22% (n=21) of the women had evidence of ascites at three months and 14% (n=13) at 
12 months, with no statistically significant difference between RALS and LT (Table 3). One 
woman in the RALS group had symptomatic lymphatic ascites that required abdominal drainage 
on two occasions.  
 
Figure 14. Anatomic distribution of intraabdominal lymphocele formation after pelvic and infrarenal paraaortic 
lymphadenectomy. Left three months postsurgery right 12 months postsurgery. Abbreviations: LT, laparotomy; 
RS, robot assisted surgery; RV, renal vein; IMA, inferior mesenteric artery; CIA, common iliac artery; EIA, external 
iliac artery; OF, obturator fossa; ILA, internal iliac artery. Illustration by Mattias Karlén. 
 
Two women in the LT group had renal infarction (one right sided and one left sided) that 
progressed between CT at three and 12 months, but no intervention was needed and no 
impairment of the renal function was observed. Of nine women (9%) with findings suggestive of 
recurrence at 12 months, four had peritoneal carcinomatosis, one had multiple lung metastases, 
two had recurrence in multiple extra- and intraabdominal sites, one had vaginal cuff recurrence, 
and one had inter-aortocaval lymph node recurrence. There was no difference in the proportion 
recurrences (Table 3). 
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Table 3. Peri- and postoperative outcomes and findings upon imaging at three and twelve        
months by surgical modality
 
 
 
	
 
 
Outcome 
Laparotomy 
(n=48) 
Robotic 
surgery 
(n=48) 
 
P-value 
Operation time (minutes) 
   Median 
   Range 
 
187 
109-300 
 
233 
166-320 
 
<0.0011 
 
Estimated total blood loss (mL) 
   Median 
   Range 
 
200 
50-850 
 
78 
20-300 
 
<0.0012 
 
Intraoperative adverse events, no. 
(%) 
4(8) 1 (2) 0.363 
Blood transfusions, no. (%) 1 (2) 0 1.03 
Admitted to intensive care unit, 
   Planned or unplanned 
 
0 
 
0 
 
Length of hospital stay (days) 
   Median 
   Range 
 
5 
4-9 
 
2 
1-5 
 
<0.0012 
 
Postoperative complications within 
30 days4, no. (%) 
   I 
   II 
   IIIa 
   IIIb 
   IVa 
   IVb 
   V 
 
 
 1 (2) 
       12 (25) 
1 (2) 
1 (2) 
1 (2) 
0 
0 
 
 
3 (6) 
  5 (10) 
2 (4) 
1 (2) 
0 
0 
0 
 
0.363 
Readmissions within 30 days, no. 
(%) 
5 (10) 3 (6) 0.823 
Postoperative day 31-365, no. (%) 
   C-D grade ≥ 3 any reason 
   Readmission any reason 
 
4 (8) 
 6 (13) 
 
7 (15) 
7 (15) 
 
0.523 
1.003 
CT at three months, no. 
   Lymphocysts 
      1st location 
      2nd location 
      3rd location 
   Ascites 
   Other 
   Recurrence 
48 
 
23 (48) 
7 (15) 
1 (2) 
7 (15) 
4 (6) 
0 
48 
 
18 (38) 
4 (8) 
0 
14 (30) 
3 (6) 
0 
 
 
0.413 
0.523 
1.003 
0.143 
1.003 
CT at twelve months5 
   Lymphocysts 
      1st location 
      2nd location 
      3rd location 
   Ascites 
   Other 
   Recurrence 
 
 
13 (28) 
3 (6) 
0 
8 (17) 
3 (6) 
5 (11) 
 
 
7 (15) 
1 (2) 
0 
5 (10) 
1 (2) 
4 (8) 
 
 
 
0.143 
0.363 
- 
0.393 
0.363 
0.743 
Abbreviations: C-D, Clavien Dindo; CT, Computed Tomography of abdomen. Range (minimum-
maximum). 1Students t-test. 2Mann Whitney U test. 3Fisher’s exact test. 4According to Clavien-Dindo 
classification of surgical complications.5 One patient in the laparotomy group died of endometrial 
cancer within 12 months and did not undergo CT at 12 months. 
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Between day 31-365 postoperatively, 13 patients were admitted to hospital. In the RALS group 
(n=7) two women had vaginal cuff rupture resulting in surgical intervention and were also 
admitted to hospital, one woman had fever and pelvic abscess resulting in intervention with 
drainage and admission to hospital, one woman fell and had rib-fractures and was admitted to 
hospital, one woman had a very early recurrence and was admitted to hospital and examined 
under anaesthesia with biopsy, one woman was diagnosed with breast cancer and admitted to 
hospital for surgical intervention and one woman had a disseminated recurrence resulting in 
admission to hospital for ChT and intervention with abdominal biopsy. In the LT arm one 
woman was admitted to hospital because of diverticulitis, one woman because of hypokalaemia, 
two women with recurrence of disease were admitted to hospital for placement of nephrostomy, 
one woman was admitted because of recurrence and required abdominal drainage of ascites and 
one woman was admitted for open heart surgery because of myxoma. 
 
 
4.1.3 Self-reported lymphoedema 
A total of 94 (98%) women completed the EORTC-QLQ-EN24 questionnaire at baseline and 
94 (98%) at 12 months after surgery.  At baseline, pre-surgery, 32% (n=15) in the LT group and 
17% (n=8) in the RALS group reported any extent of swelling in one or both legs or feeling of 
heaviness in one or both legs (p= 0.10). The corresponding figures at 12 months after surgery 
was 61% (n=28) and 50% (n=24) (p=0.31). No significant difference in mean score of QLQ-
EN24 items capturing LLL was found at 12 months after post-surgery, in relation to the number 
of pelvic or paraaortic lymph nodes, the delivery of chemo-radiotherapy or not, FIGO stage, the 
occurrence of co-morbidity, age or demographic characteristics (Table 4). A 10-point difference 
in mean score was found between BMI < 25 and those with > 30 but the difference was not 
statistically significant (p=0.13). The mean lymphoedema score and corresponding standard 
deviation at 12 months after surgery unadjusted for baseline score was 25 (28) for LT and 15 (20) 
for RALS. In univariate analysis, surgical modality (p<0.05) and abdominal drainage (p=0.02) 
were significantly associated with self-reported LLL at 12 months after surgery. However, neither 
variable was independently associated with self-reported LLL in the multivariable analysis (Table 
4). 
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Table 4.  Association between clinical factors and 12-month self-reported lower limb 
lymphoedema 
 
 
Abbreviations: SD, standard deviation; MD, mean difference; CI, confidence interval; LWP, living with partner; 
BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; BMI, body mass index. 
1The multivariate model includes the statistically significant (p<0.05) variables Operation and Drainage from the 
univariate analysis as well as baseline lymphedema score. 2Wald test.3Test for trend.4Chemotherapy followed by 
pelvic external beam radiation therapy 
 
 
   Univariate  Multivariate1  
 
Factor 
 
Level 
Mean score at 
12 months 
(SD) 
 
MD (95% CI) 
 
P2 
  
MD (95% CI) 
 
P2 
 
         
Operation Open 25 (28) Ref. 
-10 (-20 to 0) <0.05 
 Ref. 
-6 (-14 to 3) 0.19 
 
 Robot 15 (20)   
Drainage No 26 (29) Ref. 
-12 (-22 to -
3) 
 
0.02 
 Ref. 
-8 (-16 to 1) 
 
0.09 
 
 Yes 14 (19)   
Age (years) <60 24 (30) Ref. 
-3 (-18 to 11) 
-6 (-21 to 9) 0.413 
  
 
 
 60-69 20 (24)   
 70-75 18 (23)   
Married/LWP Yes 21 (25) Ref      
 No 19 (24) -2 (-13 to 8) 0.67     
Education Elementary  23 (28) Ref      
 Secondary 18 (22) -5 (-18 to 9)      
 University 21 (27) -2 (-16 to 12) 0.853     
Work At work 24 (28) Ref      
 Retired 18 (23) -6 (-17 to 4) 0.25     
BMI <25 16 (20) Ref      
 25-29 19 (24) 3 (-9 to 15)      
 >30 26 (31) 10 (-3 to 22) 0.133     
Comorbidity No 23 (27) Ref      
 Yes 17 (22) -6 (-16 to 4) 0.23     
FIGO Stage I-II 19 (24) Ref      
 III-IV 24 (28) 5 (-8 to 18) 0.42     
Chemo-
radiation4 
No 19 (24) 
Ref. 
2 (-10 to 15) 0.71 
    
 Yes 22 (27)   
Pelvic LND 9-19 17 (21) 
Ref. 
5 (-8 to 17) 
3 (-10 to 16) 0.623 
  
 
 
number of 
nodes 
20-27 22 (24)   
 28-53 20 (29)   
Paraaortic LND 2-15 20 (23) Ref      
number of 
nodes 
16-24 20 (23) -1 (-13 to 12)      
 25-51 20 (29) -1 (-13 to 12) 0.943     
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4.1.4 Health care costs 
The total cost for RALS was significantly lower than LT. When excluding the investment cost 
for the daVinci system, the cost for RALS was even lower, Table 5.  
 
Table 5. Estimated mean total cost per patient undergoing hysterectomy, bilateral 
salpingoophorectomy and systematic lymphadenectomy by surgical modality  
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: CPP, Cost Per Patient; SEK, Swedish Crowns; SD, Standard Deviation. 
* The total cost per patients included all associated costs of ward care (e.g. staff, radiology, laboratory, 
medication) as well as costs related to activities performed in the operation theatre (all surgical instruments 
and draping included), postoperative care and pharmaceuticals.1Mann Whitney U test.2Exchange rate 2013, 
1 Euro = 8.33 SEK. 4Provided 350 procedures per year per robotic system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Laparotomy 
(n=48) 
Robotic surgery 
(n=48) 
 
p-value1 
CPP* (SEK) 
Mean 
SD 
 
140,000 SEK 
21,892 SEK 
 
120,861 SEK 
27, 637 SEK 
 
<0.001 
 
CPP (Euro)2 
Mean 
SD 
 
€16,807 
€2,628 
 
€14,509 
€3,318 
 
<0.001 
CPP including investment cost for 
robot3, SEK 
Mean 
SD 
 
 
140,000 SEK 
21,892 SEK 
 
 
129,789 SEK 
27,653 SEK 
 
 
<0.05 
CPP including investment cost 
for robot, Euro 
Mean 
SD 
 
 
€16,807 
€2,628 
 
 
€15,581 
€3,320 
 
 
<0.05 
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4.2 PAPER III 
Of the 113 women in the intention-to-treat group, the EORTC-QLQ-C30 and QLQ-EN24 was 
answered at baseline by 98% (n=55) of women in the RALS group and 96% (n=55) in the LT 
group. The corresponding figures at 12 months were 100% (n=56) and 81% (n=46), see Fig. 15. 
 
Figure 15. HRQoL assessment diagram, intention-to-treat, n=113. 
Baseline characteristics/demographics, perioperative outcome did not differ substantially from 
the per protocol group, see Table 6. The majority of patients received adjuvant treatment, of 
which ChT was most commonly used (44% LT and 38% RALS). ChT followed by EBRT was 
delivered to 23% in LT group and 30% in RALS group. No patient received external beam 
radiotherapy only. 
 
ROBOT ASSISTED LAPAROSCOPIC SURGERY
Presurgery questionnaires (n=56)
Completed EORTC QLQ-30 EN 24 (n=55; 98%)
1 missing (KS049)
Completed EQ-5D-3L (n=55; 98%)
1 missing 
LAPAROTOMY
Presurgery questionnaires (n=57)
Completed EORTC QLQ-30 EN 24 (55; 96%)
2 missing (KS014,47)
Completed EQ-5D-3L (n=55; 96%)
2 missing
3 months post-surgery questionnaire
Completed EQ-5D-3L (n=55; 98%)
1 missing 
3 months post-surgery questionnaire
Completed EQ-5D-3L (n=49; 86%)
7 excluded per-operatively 
1 withdrawal 
12 months post-surgery questionnaires
Completed EORTC QLQ-30 EN 24 (n=46; 81%)
8 excluded per-operative
1 withdrawal   
2 palliative care 
Completed EQ-5D-3L (n=46; 81%)
8 excluded per-operatively  
1 withdrawal 
2 palliative care 
12 months post-surgery questionnaires
Completed EORTC QLQ-30 EN 24 (n=56; 100%)
Completed EQ-5D-3L (n=56; 100%)
Intention to treat 
(n=113)
  
 
 
 
 
 
 
42 
Table 6. Baseline demographics/characteristics and perioperative variables by surgical 
treatment, intention-to-treat
 
 
4.2.1 Health related quality of life 
The results of the EORTC-QLQ-C30 are presented in Table 7. There was a statistically 
significant difference between the two surgical groups 12-months after surgery for “nausea and 
vomiting” in favour of LT (p=0.01) but the difference of 4 (95% CI 1 to 7) between the mean 
scores is not considered “clinically important” according to EORTC guidelines. Higher cognitive 
function was reported by the LT group compared to RALS, but the difference of -6 (95% CI -14 
to 0, p=0.06) was statistically non-significant. However, a difference of -6 between the mean 
scores is according to EORTC guidelines “clinically important”. 
	
	
	
Abbreviations: SD, standard deviation; BMI, body mass index; ECOG, Eastern Cooperative 
Oncology Group; PS, performance status. 1Randomly assigned patients, intention to treat. 
2According to Clavien-Dindo Classification.  
  
 
	
 
 
 
 
 
 
 
 
 
 
 
Characteristic 
 
Laparotomy 
(n=57) 
Robotic surgery 
(n=56) 
Age, years, mean ±SD 66 ± 6 64 ± 9 
BMI, mean ± SD 28 ± 6 28 ± 6 
Weight, kg, mean ± SD 76 ± 15 75 ± 17 
ECOG PS 0, no. (%) 55 (97) 53 (95) 
Comorbidity no. (%) 
   Diabetes 
   Hypertension 
   Cardiovascular disease 
   Asthma 
   Previous malignancy 
 
3 (5) 
24 (43) 
5 (9) 
4 (7) 
6 (11) 
 
4 (7) 
23 (40) 
5 (9) 
4 (7) 
9 (16) 
Marital status, no. (%) 
   Married or living with a partner 
   Widow 
   Single 
   Other 
 
34 (60) 
2 (4) 
17 (30) 
4 (7) 
 
37 (66) 
1 (2) 
15 (27) 
3(5) 
Level of education, no. (%) 
   Elementary school 
   Secondary school 
   College/University 
 
16 (28) 
27 (47) 
14 (25) 
 
9 (16) 
24 (43) 
23(41) 
Employment status, no. (%) 
   Employed 
   Unemployed 
   Retired 
 
22 (39) 
0 
35 (61) 
 
22 (39) 
1 (2) 
33 (59) 
Adjuvant treatment, no. (%) 
   Chemotherapy 
   Chemo-radiation 
 
25 (44) 
13 (23) 
 
21 (38) 
17 (30) 
Operation time, minutes, mean ± SD  183 ± 50 229 ± 46 
Postoperative complications grade ≥ 32, no. (%) 5 (9) 4 (7) 
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 Table 7. EORTC QLQ-C30 and EN-24 scale scores at 12-months post-surgery by surgical   
modality1 
 
 
 
Abbreviations: EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire Core; QLQ-EN24, Endometrial cancer supplementary module; MD, mean difference; CI, 
confidence interval. Bold values indicate statistical significance or clinically important difference. 1QLQ- 30: 
Number of patients included in the analyses range from 99 to 100 depending on the studied scale for QLQ-EN24 
number of patients in the analyses range from 96-100 depending on studied scale. 2 Mean difference between 
surgical modality. 3Walds test of significance.4Higher scores correspond to better functioning and global Quality of 
Life.5Higher scores correspond to a higher level of problems.6For the conditional scales Sexual enjoyment and 
Sexual/vaginal problems, where information was available for 11 patients only, mean scores are not reported. 
	
	
 At 12 months 
Mean (SD) 
 
Controlling for baseline 
scores 
 
EORTC QLQ-C30 scale 
 
Laparotomy 
Robot-
assisted 
surgery 
 
MD2 (95% CI) 
 
P3 
 
Functional scales4 
    
Global health status / QoL 79 (18) 77 (18) -1 (-7 to 6) 0.82 
Physical functioning 87 (14) 87(14) 1 (-3 to 6) 0.56 
Role functioning 88 (21) 86 (23) 1 (-8 to 9) 0.90 
Emotional functioning 81(18) 82 (22) 0 (-7 to 7) 0.95 
Cognitive functioning 88(15) 81 (21) -6 (-14 to 0) 0.06 
Social functioning 88 (16) 88 (18) 3 (-4 to 9) 0.42 
 
Symptom scales/items5 
    
Fatigue 22 (20) 22 (17) 1 (-5 to 7) 0.81 
Nausea and vomiting 1 (4) 5 (11) 4 (1 to 7) 0.01 
Pain 14 (17) 13 (18) -3 (-9 to 4) 0.40 
Dyspnoea 20 (22) 20 (24) 3 (-6 to 11) 0.56 
Insomnia 25 (22) 24 (24) 1 (-8 to 10) 0.80 
Appetite loss 6 (19) 6 (13) 0 (-6 to 6) 0.99 
Constipation 17 (24) 14 (23) -1 (-9 to 8) 0.86 
Diarrhoea 6 (13) 7 (16) 2 (-4 to 8) 0.61 
Financial difficulties 5 (14) 4 (12) -1 (-6 to 4) 0.65 
 
QLQ-EN24 
    
     
Functional scales4     
Sexual interest 12 (16) 18 (22.0) 4 (-3 to 12) 0.26 
Sexual activity 11 (17) 14 (22.8) 2 (-6 to 9) 0.68 
Sexual enjoyment6 - - - - 
     
Symptom scales5     
Lymphoedema 25 (28) 16 (21) -6 (-14 to 3) 0.20 
Urological symptoms 18 (19) 15 (15) -2 (-9 to 4) 0.43 
Gastrointestinal symptoms 18 (18) 16 (15) 1 (-5 to 7) 0.80 
Poor body image 13 (19) 19 (29) 9 (-1 to 18) 0.07 
Sexual/vaginal problems5 - - - - 
Pain in back and pelvis 18 (24) 22 (26) 4 (-5 to 13) 0.33 
Tingling/numbness 25 (31) 32 (30) 6 (-6 to 19) 0.32 
Muscular pain 28 (26) 25 (25) 1 (-9 to 11) 0.83 
Hair loss 13 (31) 17 (34) 5 (-8 to 18) 0.42 
Taste change 3 (10) 7 (21) 5 (-2 to 11) 0.19 
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The results of QLQ-EN24 are presented in Table 7. The largest difference was observed for 
body image, where patients in the RALS group reported poorer body image 9 (95% CI -1 to 18, 
p<0.07). However, no statistically significant difference was found between LT and RALS in any 
EN24 score. 
 
    
Figure 16.  Proportion women reporting any problems according to the EQ-5D-3L at the assessment time-points 
by to surgical modality.  
 
The EuroQol EQ-5D-3L questionnaire was answered at baseline by 98% (n=55) of women in 
the RALS group and 96% (n=55) in the LT group. Corresponding figures at 12 months were 
100% (n=56) and 81% (n=46), respectively (Figure 1). At 12 months’ post-surgery, a larger 
proportion of women in the LT group reported any extent of impairment of mobility (26% vs. 
9%, p=0.03) as compared to the RALS group, but no other differences were observed, Fig. 16. 
There was no difference in the EQ-Visual Analogue Scale score between groups (80 in both 
groups, p=0.94), data not shown. 
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4.3 PAPER IV 
Between June 2014 and May 2018, 355 women were assessed for eligibility. 275 women were 
enrolled and 261 underwent the planned procedure. One women was excluded due to other 
malignancy on final pathology and three women (none with LNM) were operated by a non-
accredited surgeon and excluded due to protocol violation. Thus, 257 patients were analysed, see 
flow diagram in Figure 17.   
Figure 17. Flow diagram, SHREC study. Accrual June 2014 through May 2018 
 
Median age was 71 (range 44-90), body mass index 27 kg/m2 (range 17-47) and operation time 
224 minutes (range 115-440). All participants had HREC by preoperative assessment with 86% 
(n=220) remaining HREC upon final histology. The majority of patients had endometrioid 
subtype (64%). 
Assessed for eligibility (n=355)
Enrolled in study (n=275)
Planned procedure performed 
(n=261)
Analysed (n=257)
Excluded (n=80)
Not meeting inclusion criteria (n=74)
Comorbidity/Age (n=27)
Language barrier (n=11)
Disseminated disease (n=15)
Uterus too large (n=21)
Declined to participate (n=5)
Other reasons (n=1)
Planned procedure not performed (n=14) 
Excluded before injection of ICG (n= 7) 
Synchronous pancreatic cancer scheduled for laparotomy (n=1)
Low risk endometrial cancer (n=1) 
Patient withdrawal (n=1) 
No visible cervix (n=1) 
Stage IIIB scheduled for laparotomy (n=1) 
Uterus too large (n=1)
Circulatory instability and cardiac arrhythmia upon induction of 
anesthesia (n=1) 
Excluded after injection of ICG (n=7)
Disseminated disease (n=1) 
Severe retroperitoneal fibrosis due to previous radiotherapy for other    
malignancy (n=1) 
Severe adhesions converted to laparotomy (n=1) 
Disseminated disease converted to laparotomy (n=4) 
Excluded (n= 4)
Other primary malignancy upon final pathology
Surgery by non- accredited surgeon  
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4.3.1 Sensitivity and negative predictive value 
The overall pelvic SNB algorithm had a sensitivity of 100% (95% CI 92-100) and a negative 
predictive value of 100% (95% CI 98-100), see Table 8. In successfully mapped women, the 
sensitivity of the sentinel lymph node specimen was 98% (95% CI 89-100) and a negative 
predictive value of 100% (95% CI 97-100). 
 
Table 8. 2x2 table for sensitivity and NPV of the pelvic SNB algorithm 1,2
 
4.3.2 Detection rate of SLN, extent of lymphadenectomy and lymph node yield 
Prior to and after reinjection the overall mapping rate (at least one ICG positive SLN) was 95% 
and 98%, and the bilateral mapping rate was 83% and 94% respectively.  
All 257 women underwent pelvic SLN mapping and a full pelvic lymphadenectomy. IRPALND 
was performed in 208 (81%) women and in 9 (4%) women the paraaortic lymphadenectomy was 
restricted to the level of the inferior mesenteric artery. The median number of removed pelvic 
nodes was 29 (range 8-75) and paraaortic nodes 12 (range 2-51). The median number of type 1-2 
SLNs was 4 (range 1-7), see Table 9.  
 
 
 
Table 2. 2x2 table for sensitivity and NPV of the pelvic SNB algorithm 1,2 
  True positive  
 
True negative Total 
 
Positive metastasis by SNB algorithm 
 
 
54 
 
0 
 
54 
 
Negative metastasis by SNB algorithm 
 
0 
 
201 
 
201 
 
Total 
 
54 
 
201 
 
255 
Abbreviations: NVP, negative predictive value; SNB, sentinel node biopsy.1 Including side specific 
lymphadenectomy in case of non-display, resection of macroscopic lymph nodes suspicious for metastases 
and reinjection of tracer in case of non-display.2The two women with isolated paraaortic lymph node 
metastases not included in the analysis, since the algorithm exclusively evaluates pelvic lymph node 
detection.  
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4.3.3 Lymph node metastases 
56 of the 257 in the per protocol analysis had lymph node metastases. Two women (1%) had 
isolated paraaortic LNMs. A total of 54 women had pelvic LNM. In one of 54 women mapping 
failed. Of the remaining 53 women who were successfully mapped, 52 were accurately diagnosed 
with pelvic LNM in their sentinel lymph node with one having a false negative sentinel lymph 
node. However, both the non-mapped woman and the woman with a false negative sentinel 
node were identified by the algorithm through resection of suspicious macroscopic pelvic lymph 
node metastases (SLN macro) 
Nineteen of the 52 women (36%) with ICG positive metastatic SLNs had micro-metastases 
(MM) or isolated tumor cells (ITC). In three of the 23 women (13%) with paraaortic LNM, 
pelvic LNM was restricted to SLNs with only MM or ITC.   
Table 9. Extent of LND, node count, proportion metastases and successfully mapped women1 
Variable 
 
n=257 
Surgical lymph node assessment, no. (%) 
   SLN + Pelvic LND 
   SLN + Pelvic + inframesenteric paraaortic LND 
   SLN + Pelvic + infrarenal paraaortic LND 
 
40 (16) 
9 (4) 
208 (81) 
Detection of pelvic SLN, no. (%) 
   First injection of ICG 
      Unilateral 
      Bilateral 
   
   Reinjection of ICG 
      Unilateral 
      Bilateral 
 
 
244 (95) 
213 (83) 
 
 
252 (98) 
242 (94) 
Sentinel lymph node yield 
   Median 
   Min-Max 
 
4 
1-7 
Lymph node metastases, no. (%) 56 (22) 
Isolated paraaortic lymph node metastases2, no. (%) 2 (1) 
Isolated pre-sacral lymph node metastases, no. (%) 1 (0) 
Isolated parametrial lymph node metastases, no. (%) 0 (0) 
Pelvic lymph node yield 
   Median 
   Min-Max 
 
29 
8-75 
Paraaortic lymph node yield2 
   Median 
   Min-Max 
 
12 
2-51 
Abbreviations: LND, lymph node dissection; SLN, sentinel lymph node; ICG, indocyanine green. 1Analysed 
women only. 2Among the 217 women subjected to paraaortic LND. 
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Eleven women (20% of node positive patients) had pre-sacral metastases, 27% of these did not 
map along the LPP. One woman had an isolated pre-sacral metastasis. Pre-sacral metastases were 
more common in women with a non-endometrioid histology (36% compared to 10%). 108 
patients (42%) had lymph nodes in the resected parametria, eight of these women (7%) had 
metastatic parametrial nodes. None had isolated metastatic parametrial nodes.  
Of the patients with LREC upon final histopathology, three (8%) had pelvic LNM. 26% of 
women with HREC upon final histopathology (n=220) had lymph node metastases. 
 
 
Figure 18. Schematic overview of the pelvic uterine lymphatic pathways with typical localisation and proportion 
ICG positive and metastatic sentinel lymph nodes per lymph compartment. Percentages refer to; 1the total 
number of women, 2node-postive women; it is possible to have more than one ICG positive or metastatic 
sentinel lymph node. Left parametria, 18/56 women had lymph nodes of which four with metastasis. Right 
parametria, 22/56 women had lymph nodes of which five with metastasis (Data not shown). Abbreviations: 
UPP, upper paracervical pathway; LPP, lower paracervical pathway.  
 
The anatomic location of lymph node metastases and sentinel lymph nodes are presented in Fig. 
18. 
 
Left obturator area:  
ICG pos SLN1:  63% 
metastatic SLNs2:  25% 
any metastatic ln2:  34% 
 
Left external iliac area:  
ICG pos SLN1:  82% 
metastatic SLNs2:  41% 
any metastatic2:  45% 
 
 
Left presacral area:  
ICG pos SLN1:  52% 
metastatic SLNs2:  5% 
any metastatic2: 13% 
 
Left common iliac area:  
ICG pos SLN1:  13% 
metastatic SLNs2:  2% 
any metastatic2: 7% 
 
Right Obturator area: 
ICG pos SLN1:  62% 
metastatic SLNs2:  36% 
any metastatic ln2:  43% 
 
Right external iliac 
area:  
ICG pos SLN1:  80% 
metastatic SLNs2:  25% 
any metastatic2:  29% 
 
Right presacral area: 
ICG pos SLN1:  59% 
Metastatic SLNs2:  9% 
any metastatic2:  13% 
 
Right common iliac 
area:  
ICG pos SLN1:  13% 
Metastatic SLNs2:  4% 
any metastatic2:  16% 
 
 
 
 
Figure X: Schematic overview of the pelvic uterine lymphatic pathways with typical localization and percentage of 
Indocyanine green positive and metastatic sentinel lymph nodes per lymph compartment in endometrial cancer 
(percentages refer 1 to the total number of patients/ 2 node-positive patients; patients can have more than one ICG 
positive or metastatic sentinel lymph node). UPP = upper paracervical pathway. LPP = lower paracervical pathway. 
Left parametria: lymph nodes in 18/56 patients, of which four with lymph node metastases 
Right parametria: lymph nodes in 22/56 patients, of which five with lymph node metastases 
UPP 
LPP 
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4.3.4 Perioperative adverse events and postoperative complications 
All women in whom ICG was injected (n=268) were analysed for adverse events and 
postoperative complications, see Table 10. Five women were converted to laparotomy due to 
disseminated disease (n=4) or intraabdominal adhesions (n=1) following ICG injection but prior 
to docking the robot. No adverse events occurred during injection of ICG or during the sentinel 
node procedure per se. In total, eight (3%) patients experienced a per-operative complication.  
 
Table 10. Perioperative adverse events and postoperative complications1
 
Eighty-five (32%) women had a postoperative complication within 30 days of after surgery 
(Table 10). Nine women (3%) experienced a serious adverse event (SAE), three during and six 
after surgery. Five of the six postoperative SAEs were categorized as such due to prolonged 
hospital stay (> 5 days). The readmission and reoperation rate within 30 days after surgery was 
3% and 7% respectively. 
Table 4. Perioperative adverse events and postoperative complications1 
Variable 
 
n=268 
Adverse Events, no. (%) 
    
   Before docking the robot2 
      Conversions to laparotomy 
         Disseminated disease 
         Intraabdominal severe adhesions 
         Trendelenburg position not tolerated 
         Bleeding during surgery 
    
   During Sentinel node dissection 
      None observed 
    
   During completion PLND ± PALND 
      Large vessel injury 
      Nerve injury 
      Bowel injury 
    
   During hysterectomy 
      None observed 
 
 
 
9 (4) 
4 (1) 
1 (0) 
1 (0) 
3 (1) 
 
 
 
 
 
8 (3) 
6 (2) 
1 (0) 
1(0) 
 
 
0 
Postoperative 30 day complications3, no. (%) 
   I 
   II 
   IIIa 
   IIIb 
   IVa 
   IVb 
 
36 (13) 
28 (10) 
14 (5) 
5 (2) 
1(0) 
1(0) 
Readmissions to hospital4, no. (%) 9 (3) 
Abbreviations: PLND, pelvic lymph node dissection; PALND, paraaortic lymph node 
dissection.1 All women enrolled in whom ICG was injected in the uterine cervix (intention to 
treat.) 2During injection of ICG, insufflation, port placement and conversions to laparotomy. 
3According to the Clavien Dindo classification. 4Within 30 days after surgery. 
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5 DISCUSSION 
 
5.1 PAPER I-III 
The studies from the RASHEC trial demonstrate that robot-assisted laparoscopic surgery is non-
inferior to laparotomy in harvesting paraaortic lymph nodes both above and below the inferior 
mesenteric artery. Moreover, that RALS provides lower health care costs. Furthermore, our 
results suggest that there are no differences between LT and RALS in short- or long term 
complications, lymphatic side effects and HRQoL.  
The current surgical management of endometrial cancer is largely based on the 
patterns of lymphatic dissemination described in a prospective study from the Mayo clinic 11. A 
large proportion of paraaortic metastases was found to be located between the renal vein and the 
IMA and the former practice of limiting the PALND to the IMA was proven insufficient. The 
lack of international consensus regarding lymph node count as a quality indicator for 
comprehensive staging is illustrated by the vast discrepancies between the ESMO-ESGO-
ESTRO guidelines and the benchmarking data from the Mayo clinic. In the former, a minimum 
number of 10 nodes in total is required whereas the latter defines comprehensive staging to 
include at least 22 pelvic and 10 paraaortic lymph nodes 118.  Increasing the number of harvested 
lymph nodes or the extent of lymphadenectomy may have clinical implications with improved 
survival in patients with high-risk disease 24,125-127. Whether this is suggestive of a therapeutic 
effect of lymphadenectomy or merely represents a more accurate staging is unknown. In our 
study, the paraaortic lymph node count as well as the proportion of metastases in the ITT 
analysis was consistent with previous reports 128. Furthermore, the locations of lymph node 
metastases were also coherent with previous data and reproduces previously described patterns 
of lymphatic dissemination 11. Interestingly, we found a significantly lower pelvic node count 
after RALS. These data corroborate with recent findings suggesting that minimally invasive 
surgery may result in a lower number of harvested pelvic lymph nodes 129. However, the mean 
number of pelvic nodes after RALS met the quality criteria suggested by the Mayo clinic 118.  
RALS was associated with fewer per- and postoperative complications than LT, 
albeit not statistically significant. More importantly, the number of major postoperative 
complications (Clavien-Dindo > 2) was the same between the groups, contrary to previous 
reports 130,131. Comparing complications between studies poses difficulties since the grading 
systems, definitions and cohort sizes vary considerably. In a relatively recently published 
systematic review comparing RALS with LT for endometrial cancer, the majority of included 
studies showed no significant differences in perioperative complications 29.  
The proportion of women with long-term adverse events and admissions to hospital between 
one and 12 months after surgery, for any reason, did not differ. In total, two women were 
diagnosed with unilateral renal infarction by computed tomography after LT, 
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 though without impairment of renal function. This unexpected and potentially serious 
complication would have gone unnoticed without follow-up imaging as part of the study 
protocol. The risk of “silent” injury to the renal arteries during IRPALND is unknown, but 
experiences from retroperitoneal lymph node dissection in testicular cancer patients, suggest a 
1.4-4% risk of per-operative renal artery injury 132,133. 
Since consensus on standardized measures and definition of LLL are lacking, 
dispersion of reported incidence and prevalence estimates after endometrial cancer treatment is 
wide, ranging between 5-38% and 0-50% respectively 33-35,39,40. After IRPALND, the proportion 
of patients with LLL, has been reported to 18% and 37% for robot-assisted surgery and LT 
respectively 41,42.  Proportions reported in our study were higher with 54% of all women 
reporting any extent of LLL symptoms 12 months after surgery. In contrast to our study, 
lymphoedema assessment in the study by Geppert et al was performed by a physiotherapist using 
the CTC version 3.0 classification 41. It is widely accepted that patient-reported outcomes differ 
from estimations by health care providers 134-136. In line with the recommendation from GCIG 
we used a validated questionnaire, in this case the EORTC QLQ-EN24, to capture the 
occurrence of symptoms indicating lower limb lymphoedema 137. In a Swedish study by 
Bergmark et al, heavy or swollen legs and/or lower abdomen were reported at least occasionally 
by 39% to 41% of patients 5 years after radical hysterectomy for cervical cancer 138.  In our study 
of endometrial cancer patients, the median age and rate of comorbidities was higher compared to 
cervical cancer patients in Sweden, which may have contributed to a higher prevalence of 
reported symptoms. The uneven distribution of women reporting any extent of LLL at baseline 
despite randomisation may be attributed to chance and might have been balanced if the sample 
size of the study was larger. 
Risk factors associated with LLL include lymphadenectomy, number of harvested pelvic lymph 
nodes, external beam radiotherapy and obesity 33-38.  Clearly, surgical disruption of lymphatic 
channels or radiation-induced fibrosis constitute reasonable causes of treatment related 
lymphoedema. However, the heterogeneity in reported symptoms from treated patients illustrate 
the complexity of the underlying pathophysiology. Indeed, obese women may suffer from 
lymphoedema without prior surgery or radiation and obesity may aggravate therapy-induced 
symptoms 139,140.  
None of the mentioned risk-factors were associated with lymphoedema in our study. Paraaortic 
lymph node yield had no association with LLL with the same mean lymphoedema score at 12 
months regardless of lymph node yield, suggesting that the paraaortic lymphadenectomy per se 
does not add to LLL. Furthermore, abdominal drainage was not associated with a decrease in 
self-reported LLL.  
It has been suggested that minimally invasive surgery (MIS) significantly decreases the incidence 
of lymphocysts identified by ultrasound after lymphadenectomy 43. In our study, lymphocyst 
formation (or ascites) on computed tomography of abdomen did not differ between surgical 
modality.  
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Interestingly, paraaortic lymphocysts were more prevalent after RALS in contrast to pelvic 
lymphocyst formation. Compared to laparotomy, RALS requires a smaller incision of the 
paraaortic peritoneum to prevent the bowels from obstructing the surgical field. This may result 
in quicker healing of the peritoneum and may explain the larger number of paraaortic 
lymphocysts. However, the frequency of observed lymphocysts or ascites had no clinical 
implication and no agreement with lymphoedema score 12 months after surgery. 
 Two previous trials, that included mandatory comprehensive surgical staging 
comparing surgical modalities in relation to HRQoL outcomes, have been conducted.  The 
GOG LAP2 trial, where pelvic and inframesenteric paraaortic lymphadenectomy was performed, 
assessed HRQoL by the Functional Assessment of Cancer Therapy Scale-General (FACT-G) 
questionnaire 49,141. The only significant difference in favour of laparoscopy at 6 months’ follow-
up was body image, though no clinically important difference (CID) was met 48. In the study by 
Zullo et al, where pelvic lymphadenectomy was mandatory and paraaortic lymphadenectomy 
performed in 7%, the Short Form Health Survey 36 (SF-36) questionnaire was used. The authors 
observed favourable outcomes for laparoscopy in all domains of the questionnaire at 6 months, 
but measures of clinically important differences were not reported 50,142.  
Based on the previous result of these studies, we expected to find significantly better HRQoL 
among women treated with RALS in our study. However, the only statistically significant 
difference in mean scores was observed in favour of LT for nausea/vomiting. The mean 
difference was small and did not meet CID 123. We therefore find it unlikely that this finding has 
any relevance for the treated women. Cognitive impairment have been reported after surgery, 
though the underlying mechanisms are not fully understood 143 . 
 Although not statistically significant, a small clinically important difference in cognitive 
functioning in favour of LT was observed in the current trial. The Trendelenburg position 
required for robot assisted pelvic surgery might be associated with cerebral hypoxia, though 
reports are scarce 144. Furthermore, it is well known that ChT may result in cognitive impairment 
145.  Whether this finding has any relevance must be further explored in larger trials.  
Given that the only difference in HRQoL reported in the LAP2 trial was superior body image 
after MIS, we were surprised to find similar mean scores in both treatment arms in the current 
trial. The larger incision required by laparotomy to access the infrarenal area should reasonably 
lead to a poorer body image in the LT arm. On the contrary, a CID was apparent in favour of 
LT, although not statistically significant. Several studies support the results from the LAP2 trial, 
reporting better cosmetic satisfaction after MIS. Higher level of satisfaction with scar cosmesis 
does not, however, necessarily translate to better body image 146-149.  
It could be argued that a full midline scar is a constant visual reminder of the patient’s cancer 
diagnosis, which conceptualizes a different frame of reference that remains in the long-term.  
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Furthermore, the mean age in our study could reflect a different attitude and acceptance in 
elderly women. Finally, cultural differences between countries in which the studies were 
conducted may affect the response 48,80. 
Statistically significantly fewer women in the RALS reported any extent of mobility impairment 
in the EuroQoL EQ5D-3L one year after surgery as compared to LT. Few women reported, 
however, any extent of impairment (LT n= 12, RALS n=9). In addition, no between group 
differences were found for the other four questions including the EQ5D VAS score. The results 
should be interpreted cautiously, especially since no adjustments for baseline score were made. 
Possible explanations for the observed differences in HRQoL between the current and previous 
trials include the duration of follow-up and the extent of surgical staging. In both the LAP2 and 
the trial by Zullo et al, 6 months’ follow-up were used whereas our long-term assessment 
encompasses the end of adjuvant treatment, with follow up 12 months after surgery. It is 
possible that the favourable HRQoL outcomes reported in previous trial would have been less 
apparent 6 months later. Whether the more extensive staging procedure applied in the current 
study mitigates the effect of minimally invasive access on HRQoL remains speculative. 
A major concern regarding RALS is the associated costs for acquisition, 
maintenance and single-use equipment. Several studied have identified robot-assisted surgery as a 
major cost driver although cost efficiency may be achieved in high-volume settings 91. In 
comparison with conventional laparoscopy, RALS is generally considered more expensive but 
effects of the initial learning curve may have biased early reports 150,151. In spite of higher 
procedural costs and longer operation time, we demonstrate a significantly lower cost after 
RALS, even when capital costs were included. The saving is mainly due to the considerably 
shorter length of hospital stay but other factors e.g. less need for postoperative analgesia, 
contributed to the result.  
As most women in the RASHEC trial were retired, the cost for absence from 
work and sick-leave, which would undoubtedly be in favour of RALS, is not included in the 
analysis.  Moreover, in the setting of the RASHEC trial, all women who were subjected to 
laparotomy regardless of diagnoses, were offered in-patient post-operative rehabilitation at a 
health care facility outside the hospital. Neither these costs that most certainly would be lower 
for RALS, were included in the analysis. Nonetheless, the finding should be interpreted with 
caution. It is important to stress that the cost savings was achieved in a high-volume institution 
with highly experienced surgeons and the generalizability of these results can be questioned. 
In the intention-to-treat analysis, four women randomised to RALS did not receive planned 
procedure due to inability to access the paraaortic surgical field. In addition, one patient was 
converted to laparotomy. Consequently, 9% (n=5) of patients did not receive planned surgical  
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procedure because of inherent limitations of RALS. However, this proportion is considerably 
lower than the 25% reported for traditional laparoscopy141. Conversion to LT was low (1.8%) 
and supports the notion that RALS entails less conversion than conventional laparoscopy152 
5.2 PAPER IV 
The SNB algorithm applied in the SHREC trial demonstrate a sensitivity to identify pelvic LNM 
of 100% with a technical bilateral success rate exceeding 90%. No adverse events related to the 
sentinel node procedure per se were recorded. 
The sensitivity and bilateral mapping rate demonstrated in the SHREC trial is higher than 
previously reported. The pooled bilateral SLN detection in a recent systematic review was only 
61% whereas the sensitivity was 94% 153.  In order to replace systematic staging in EC, the 
technical success (i.e. bilateral mapping) of the SNB algorithm must ensure a low rate of 
lymphadenectomies.  In the SHREC trial, a total of four pelvic lymphatic pathways were 
evaluated as previously described 61. Furthermore, the total dose and number of injection sites in 
the cervix was higher than in the FIRES trial. Moreover, reinjection of ICG was permitted in 
case of uni- or bilateral failure to map the lymphatic pathways. The latter resulted in an increase 
of successful mappings from 83% to 94% and only 6% of the study population would have 
required additional lymphadenectomy if the SNB algorithm had been standard of care. Even in 
the absence of reinjections, a remarkably high bilateral mapping was observed.  
This finding suggests the need of a strict surgical and anatomical algorithm, albeit surgical 
proficiency may have contributed to the results.   
Contrary to other studies, the SHREC trial only considered pelvic disease in the SNB algorithm. 
As a result, the two women with isolated paraaortic metastases were not included in the analysis. 
A SLN was defined as the juxtauterine node in the pelvic lymph node basins. Consequently, a 
paraaortic SLN would require the complete absence of nodes along the mapped pathways in the 
pelvis. Given that more than 250 women were mapped in the SHREC trial, we find it unlikely 
that paraaortic SLNs can be detected by the current SNB algorithm. Whether peri-tumoural 
injection of tracer would enable identification of the afferent lymphatic pathways along the 
infundibulo-pelvic (IP) ligament with associated paraaortic SLNs remains to be demonstrated. 
Clearly, the inability to detect extra-pelvic disease limits the diagnostic accuracy of the pelvic SNB 
algorithm. However, the pelvic SNB algorithm is supported by the lower rate of isolated 
paraaortic metastases than previously reported 11,17,154. We speculate that the high mapping rate 
and, as suggested by other authors, the use of ultrastaging accounts for this finding. 72,73. Indeed, 
ultrastaging identified low-volume disease (Micro-metastases or ITC) in 13% of SLNs associated 
with paraaortic metastases, decreasing the rate of what would have been considered isolated 
paraaortic metastases from 2% to 1%. Consequently, low-volume disease in pelvic SLNs may be 
a risk factor for paraaortic LNM. Furthermore, only 0.4% had isolated presacral LNM, 
suggesting that the identification of the LPP can be omitted, which further simplifies the 
procedure. 
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There were no adverse events related to injection of ICG or the sentinel lymph node procedure 
in contrast to 3% during completion lymphadenectomy. This emphasizes the potential for 
reducing morbidity with a SLN concept compared to a full pelvic and paraaortic 
lymphadenectomy. The rate of postoperative more serious complications (Clavien Dindo > II) 
within 30-days was 8% and consistent with previous reports 154. 
The strength of this trial includes the prospective design, with consecutive recruitment of women 
within a publicly available health care system. Moreover, only women with HREC and thus a 
higher prevalence of LNM were included and the majority were subjected to a full staging 
procedure including IRPALND. Furthermore, the definition of the surgical procedure was exact 
and performed by five accredited surgeons within two tertiary referral centres resulting in a high 
internal validity. All surgeries in the SHREC trial were performed by highly experienced surgeons 
and the generalizability of the results can be questioned. The study was also limited by 
differences in histologic assessment of excised lymph nodes where ultra-staging was performed 
on sentinel node specimens only.  
The SHREC trial is the largest trial investigating the SNB algorithm in HREC, 
corroborating the results from the FIRES trial where the majority of women had LREC. The 
results from the SHREC trial represent a paradigm shift in surgical staging of high-risk 
endometrial cancer. With a satisfactory detection rate and a complete sensitivity to detect pelvic 
lymph node metastases, the sentinel node algorithm should replace lymphadenectomy in women 
with high-risk endometrial cancer. Future trials should address the optimal management of 
women with SLN positive disease.  
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6 METHODOLOGICAL CONSIDERATION  
 
6.1 PAPER I-III 
 
6.1.1 The Randomised Controlled Trial (RCT) 
The RCT is the most reliable scientific method of comparison, primarily because of the 
randomisation that minimises risk of accidental bias and confounding. Weaknesses include that a 
RCT cannot compensate for confounding during follow up and imbalances between groups that 
can still occur by chance (sample size important). The RCT may have different hypotheses.  
The aim of the superiority trial is to establish if one treatment is better than another or placebo. 
The null hypothesis (H0) is that there is no difference between the two treatment arms whereas 
the alternative hypothesis (HA) states that there is a difference between the experimental group 
and control. If the new treatment fails to be superior, the conclusion that the treatments are 
equal or the interventional treatment is worse cannot be drawn (if a predefined non-inferiority 
margin has  not been decided in the study protocol) 155. 
The non-inferiority trial aims to establish if a new treatment is as good as an existing, motivated 
by that there are other advantages of the new treatment (e.g. toxicity profile, complications, 
health care costs). The H0 of the non-inferiority trial states that the new treatment is inferior or 
worse than the control by more than the chosen non-inferiority margin (∆), see Fig. 19. The HA 
states that the new treatment is inferior to the control treatment by less than ∆. For this reason, it 
is of utmost importance that the chosen non-inferiority margin is relevant, carefully considered 
and motivated for the basic validity of the trial design 156.  
The statistical assumption of a non-inferiority trial is often more difficult to understand than the 
relatively straightforward assumptions of the superiority trial. In addition, both superiority and 
inferiority can be demonstrated with a non-inferiority design. However, if the upper and lower 
bounds of the confidence interval crosses the ∆ and 0 (or 1 depending on measure of 
comparison) no other conclusion can be drawn other than that the intervention has not 
demonstrated a non-inferiority157.  
The non-inferiority margin of the RASHEC trial was based on previous literature on reported 
lymph node yield and from a pilot study. Nonetheless, lymph node count is not universally 
defined. There are no anatomic studies on mean number of infrarenal lymph nodes in the human 
female and lymph node count is very much at the discretion of the pathologist’s exactitude.  
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The chosen non-inferiority margin which forms the absolute basis of the trial, can thus be 
criticised. 
Figure 19. Different possible outcomes with point estimates and accompanying CI that can be interpreted in a 
non-inferiority trial. Blue boxes with bold letters are the hypothesis of the RASHEC trial: the H0 states that the 
difference of means between number of paraaortic lymph nodes between LT and RALS is higher or equal to 
the chosen non-inferiority margin of -6 paraaortic lymph nodes. The HA states that the mean difference in 
number of paraaortic lymphnodes between LT and RALS is less than the chosen non-inferiority margin of -6 
lymph nodes. In brackets are the corresponding hypothesis of a superiority trial.  
Abbreviations; H0, null hypothesis; HA, alternative hypothesis; LT, laparotomy; RALS, robot-assisted surgery; 
CI, confidence interval.  
 1The CI indicates non-inferiority since Δ is not included, but RALS is here significantly worse than LT why 
inferior. 2The CI is inconclusive and the true difference between RALS and LT might less than Δ, but RALS is 
significantly worse than LT why inferior.  
6.1.1.1 Randomisation 
The RASHEC trial was open labelled, meaning that both the participant and treating surgeon 
knew which intervention the participant was allocated to after randomisation. This can result in 
selection bias (see 6.1.1.4.1, Selection bias), e.g. if a patient would withdraw consent because of 
the allocated treatment.  
It would have been possible to mask the patient, at least for a couple of weeks postoperatively, if 
all other aspects of surgery would be constructed for this reason (e.g. sham robot theatre, sham 
epidural analgesia, sham dressings etc.). However, the implementation of such a strategy in 
0
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Non-inferiority margin
Non inferior and superior
Non inferior and  not superior
Non inferior and not superior
Non inferiority not shown
Non inferior and inferior1
Inferior and not 
non inferior
CI has to cross 0 and not cross the	" to be significant
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H0: Laparotomy – Robotic surgery ≥	∆
(H0: Laparotomy = Robotic surgery)
HA: Laparotomy – Robotic surgery < ∆
(HA: Laparotomy ≠ Robotic surgery)
Non inferiority not 
shown and inferior2
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clinical practice would not be realistic. For obvious reasons, the surgeon could not be masked as 
to which treatment the participant would receive.  
To ensure a reasonably even distribution of RALS or LT, the only practical randomisation 
technique that enabled the RASHEC trial to be conducted was block-randomisation.  
Each patient drew a sealed envelope at the out-patient clinic. Ideally this should have been 
performed at an external and independent entity without any other direct contact with the study 
participants. One could also argue that other more modern methods, like computer generated 
random numbers would be more appropriate. 
6.1.1.2 Intention-to-treat vs per protocol analysis 
The final analysis in a trial is based on the group of participants with intention-to-treat. For this 
reason, the value of the randomisation regardless of events followed is preserved. Participants 
with good compliance who follow the protocol from randomisation to end of the study might be 
different from those who do not. Consequently, analysis of the per-protocol group only might 
flaw the results. Furthermore, it is possible that known and unknown factors could have changed 
since randomisation.  
The objective of Paper I-II was to examine participants subjected to infrarenal paraaortic 
lymphadenectomy, consequently the analyses are based on the per-protocol group. A consort-
flow diagram was provided to inform the reader on possible biases of the analyses.  
6.1.1.3 Proxy outcomes 
The aim of the RASHEC trial was to examine surgical “oncologic safety” of RALS compared to 
LT in harvesting infrarenal lymph nodes. Number of lymph nodes harvested served as a proxy 
for proportion detected metastases. We thus assumed that node count and proportion 
metastases are inherently related. A sample size calculation based on patients with high risk 
endometrial cancer and paraaortic lymph node metastases resulted in thousands of participants 
and conducting such a trial was not realistic in a doctoral education. As a result, number of 
paraaortic lymph nodes harvested was chosen as a proxy, where the power calculation could be 
precise, the non-inferiority margin based on previous publications and the sample size 
manageable. 
It is important to bear in mind that a proxy outcome does not necessarily translate 
into a relevant clinical outcome.  
6.1.1.4 Internal validity 
Internal validity refers to systematic errors or systematic deviations from the truth in a study.  
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Systematic errors may result in incorrect results and conclusions, i.e. erroneous results because of 
systematic flaws in study design. Systematic errors remain even if the sample size increases 
infinitely.  
Surgical proficiency is difficult to quantify and the definition of a surgical procedure is often not 
the same or exact between institutions and surgeons.  
Therefore, surgical trials that recruit from multiple sites always carry a problem with internal 
validity.  
Since the RASHEC was a single institution trial with exact definition of the surgical procedures, 
few participating surgeons and pathologists, one could argue that the internal validity of the study 
is high.  However, only one surgeon performed the RALS procedures versus five for LT why the 
internal validity can be criticised.  
There are three main errors/biases that constitute systematic errors:  
6.1.1.4.1 Selection bias 
Is defined as when the association between an exposure and an outcome differs between subjects 
in the study and subjects not in the study. In a RCT, there is a risk of selection bias related to the 
inclusion and exclusion criteria, a poor randomisation or masking and uneven drop outs/missing 
data at follow up.   
The RASHEC trial was open labelled which may constitute a source of selection bias (see 3.2.1.1. 
Randomisation). Moreover, to avoid drop outs and protocol violation, the inclusion criteria only 
permitted healthier and younger participants with ability to understand the written information. 
Furthermore, of the 143 women assessed for eligibility, eight declined to participate. These are all 
possible sources of selection bias.  
In paper III, the follow up at 12-months post-surgery was unevenly distributed where fewer 
participants in the laparotomy group completed the HRQoL questionnaires. This might lead to 
selection bias but also to information bias (see below).  
 
6.1.1.4.2 Information/observation bias 
Is defined as errors in measuring an outcome because of poor or flawed collection of data. 
Non-differential misclassification is a problem to a lesser extent since the bias is even between 
groups of comparisons. However, this type of bias can dilute the strength of a real association. 
There is always a risk of non-differential misclassification in a study.  
Differential misclassification is more serious since it is non-proportional and differs between groups 
of comparisons and can thus create false results. In paper III, the uneven distribution of the 
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completed HRQoL questionnaires at 12-months post-surgery clearly poses a risk of differential 
misclassification. The participants in the laparotomy group who did not answer the follow up 
questionnaires might have been patients with serious symptoms and a decreased HRQoL (or the 
opposite). 
6.1.1.5 Confounders 
A confounder is defined as a factor associated with the outcome (but is not a cause of the 
outcome) and the exposure (but not an effect of the exposure). A confounding factor misleads 
the interpretation of an association but is not a bias per se, i.e. it does not create untrue 
associations. In a RCT, the randomisation is the premier way of addressing known and unknown 
confounders. If confounders are present, they would (ideally) be equally distributed between 
groups of comparisons. Furthermore, restriction of participants (i.e. to have inclusion/exclusion 
criteria that minimises distribution of unequal groups) need consideration to avoid confounding.  
When analysing data, multivariable statistical models can also reduce the risk of confounding. 
In Paper II, the proportion of women reporting any extent of self-reported lymphoedema at 
baseline was uneven despite randomisation.  The baseline scores were consequently adjusted for 
this skewness and thus also the risk of confounding. With a larger sample size in the RASHEC 
trial, a more even distribution would have been likely. Moreover, on univariable analysis, both 
surgical modality and abdominal drainage were significantly associated with self-reported LLL at 
12 months, but did not remain independently associated in multivariable analysis.  
 
6.1.2 Random error/precision 
As opposed to systematic errors, random errors cause imprecise albeit correct results, i.e. large 
confidence intervals though the true estimate lies within the confidence interval. Larger trials 
have less risk of random error.  
The risk of random error is higher if multiple comparisons are made, since every 20th result 
depends on chance at a significance level of 5%. There are ways to adjust for multiple testing e.g. 
Bonferroni correction, where the significance level for multiple testing is corrected and the 
significance level adjusted. 
In paper II, a multivariable analysis was performed and the variables were carefully considered. 
None of our chosen predictors were significantly associated with the outcome (self-reported 
lower limb lymphoedema at 12-months post-surgery) why the need to correct for multiple 
testing was not relevant. Similarly, in paper III, multiple questions were answered within the 
HRQoL questionnaires without any adjustment for multiple comparisons. Nonetheless, it could 
be argued that not adjusting for multiple tests is incorrect.  
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6.1.3 External validity 
External validity refers to reproducibility, i.e. would we get the same results in a different 
population or setting. Participants in a trial may differ from those who do not. They might be 
younger, healthier, have higher education etc. A multicentre study has a better external validity by 
definition. Our present study lacks a multicentre design, however, the trial setting was within a 
population-based health care system with all patients referred to one hospital which strengthens 
the generalisability, at least in comparison to countries with similar living-standards and health 
care systems. Nevertheless, external validity is a weakness of the RASHEC trial. 
6.1.4 Secondary outcomes from a RCT 
Paper II and III solely investigated the secondary outcomes of the RASHEC trial. It is important 
to emphasise that no power and sample size analysis were conducted for the secondary 
outcomes. However, a post hoc analysis was performed based on the outcomes of paper II 
(mean score of self-reported LLL and standard deviation for LT and RALS) resulted in a sample 
size of 200 women. The actual sample size provided a power of 53%, i.e. the certainty of no 
mean difference in self-reported lymphoedema score at 12-months between surgical modalities 
equalled a coin-flip.  
6.1.5 Measuring HRQoL  
Most data regarding health related quality of life (HRQoL) is binary (yes or no) or ordinal with 
three or more categories of responses. For comparison between groups, ordinal or binary logistic 
regression may be applied. The measure of comparison would then be relative (odds ratio) which 
is difficult to interpret. Furthermore, different scales within a questionnaire would be evaluated 
with different regression models, which also makes comparisons difficult. For this reason, many 
questionnaires are transformed to a “continuous” scale (0-100). This transformation enables 
linear regression where absolute risks (RD and RR) are the measure of comparison. Easier 
interpretation of the results is thus enabled. Since date in QoL is often very skewed, the 
assumption of normal distribution for linear regression is almost never met. For this reason, 
there are non-parametric methods to validate the results from the linear regression 119 .  
What does it mean if a comparison of reported HRQoL has a statistically significant difference? 
Does it correlate to a real-life experienced difference for the patients? 
To address this question a minimally or clinically important difference has been introduced. In 
1998, Osoba et al validated a “subjective significance questionnaire”. Participants rated their 
perception of change, since answering the EORTC-QLQ-30 questionnaire last.  
A 7-category subjective significance questionnaire, ranging from “much worse” to “much better” 
was evaluated123. In addition, the EORTC-QLQ-30 was responded to at the same time.  
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The mean change in score of the QLQ-30 was then correlated to the 7 categories of answers in 
the subjective significance questionnaire. The results concluded that a ”little” change (for better 
or worse) in the subjective significance questionnaire correlated to a mean change in QLQ-30 
score between 5-9, “moderate” between 10-20 and “very much” greater than 20. The 
participants of the study were patients with recurrent/metastatic breast cancer or extensive stage 
small cell lung cancer, recruited from two randomised trials for different chemotherapy regimens. 
The reproducibility of clinically important difference scores of Osoba et al in early stage 
gynaecologic cancer patients and in patients not treated with ChT has not been thoroughly 
investigated. Nevertheless, there is consensus in using these scores.  
How do we interpret a clinically important difference not accompanied by statistical significance? 
If the sample size is small, the chance of this event is high as opposed to the contrary, i.e. risk of 
a statistically significant difference if the sample size large enough. HRQoL outcomes from a trial 
must be put in to context and interpreted accordingly.  
In the papers from the RASHEC trial we chose to regard mean differences that were both 
statistically significant and clinically important as relevant.  
 
6.2 PAPER IV 
Paper IV was a non-randomised controlled trial with each woman being her own control. The 
main outcome was the diagnostic accuracy of a sentinel lymph node algorithm.  
 
6.2.1 Measurements of a diagnostic test - diagnostic accuracy 
The accuracy of a diagnostic test primarily depends on three interrelated measures: sensitivity, 
specificity and prevalence of disease.  
The sensitivity measures the proportion of patients with illness that the test has identified (true 
positive). In the SHREC trial, this translated to number of participants with lymph node 
metastases that the SNB algorithm detected as compared to gold standard (lymphadenectomy).  
The specificity measures the proportion of patients without disease that the test has identified as 
not having disease (true negative). In the SHREC trial, the specificity was not relevant since false 
positive SLNs were not possible, see Fig. 19).  
Unlike sensitivity and specificity that measures the tests ability to “spot” the disease/non-disease, 
the negative and positive predictive values measure how well a test can predict disease/non-
disease.  
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Positive predictive value (PPV) is the probability that subjects with a positive test truly have the 
disease. In analogy with the specificity, the PPV was not an applicable measure in our trial (no 
false positives are possible), see Fig. 20. 
The negative predictive value is the probability that subjects with a negative test truly do not have 
the disease. The NPV is dependent on prevalence of disease, and will be higher if the prevalence 
is low. In the SHREC trial, the NPV is one of two main outcome measures. 
 
 Figure 20. 2x2 table. Abbreviations: SLN; sentinel node; LND, lymphadenectomy.  
There are some aspects of the trial and the NPV that warrants discussion. The NPV was 
calculated from analysed participants in the per-protocol group, excluding those with isolated 
paraaortic LNM (n=255). One could argue that the 7 participants from the intention-to-treat 
analysis (excluded after injection of ICG in the uterine cervix) should be included and treated as 
SNB algorithm negative for metastases. The strength/weakness of the diagnostic test in real life 
would then truly be investigated. However, of the seven patients excluded after injection of ICG, 
only two were subjected to lymphadenectomy (without metastases) why the results would not 
have differed.  
6.2.2 Histopathological assessment of sentinel and non-sentinel lymph nodes 
3.2.1.1 Differential misclassification 
The histopathologic assessment of the sentinel lymph nodes (intervention) were different 
(ultrastaging) than for the non-sentinel lymph nodes (conventional sectioning). This poses issues 
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with systematic error per definition. Ideally the non-sentinel lymph nodes should also have been 
evaluated with ultrastaging.  Alternatively, the study could have been designed without 
ultrastaging of the sentinel lymph nodes to avoid information bias.   
3.2.1.2 External validity 
The assessment of sentinel lymph nodes with ultrastaging results in increased number of Isolated 
Tumour Cells (ITC), which are considered to be lymph node metastases in the study.  
The clinical implication and prognosis of women with ITC in endometrial cancer is currently 
unknown. As a result, ultrastaging of sentinel lymph nodes performed in this study results a new 
entity of lymph node “metastases” with unknown clinical implication, and might therefore flaw 
the external validity of the trial. For these reasons and to better inform the readers, the paper 
states that the trial examines the sentinel node biopsy concept /algorithm which includes ultrastaging 
and not only sentinel node biopsy.  
There were only five accredited surgeons within two tertiary high volume referral centres that 
performed the surgeries, why the generalisability of the SHREC study might be compromised.  
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7 CONCLUSION 
 
 
• Robot assisted surgery is non-inferior to laparotomy in harvesting infrarenal 
paraaortic lymph nodes.  
 
 
• Robot-assisted surgery for extirpation of the inner genitalia with pelvic and 
infrarenal paraaortic lymphadenectomy is associated with lower health care 
costs when performed by high-volume surgeons. 
 
 
• No benefits for robot-assisted surgery over laparotomy was observed for 
perioperative morbidity and QoL but larger trials are warranted for 
definitive conclusions. 
 
• Sentinel node biopsy with ultrastaging should replace lymphadenectomy as 
gold standard for diagnostic lymph node assessment in women with 
endometrial cancer 
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8 FUTURE PERSPECTIVES 
 
 
To date, no trial has answered one of the most important questions 
for women with endometrial cancer: does lymph node assessment add any information that 
can alter their prognosis for the better?  
 
• There is a need to establish if lymph node assessment is beneficial or not in 
women with endometrial cancer. A large randomised trial with the intent to 
give answer to this crucial question started accrual April 2017 and a decade 
remains until final results (The STATEC trial 
(https://clinicaltrials.gov/ct2/show/NCT02566811). 
 
• The role of adjuvant treatment in women with stage IIIC EC needs to be 
investigated.  
 
 
• The potential therapeutic benefit of extended lymphadenctomy needs to be 
explored.   
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9 APPENDICES 
9.1 PREVIOUS STAGING ACCORDING TO FIGO 
 
 
1950-61 1st FIGO staging of endometrial cancer--Clinical 
Stage 0 Cases which the pathologist considers most likely to be of a carcinomatous 
nature though it is impossible to arrive at a definite microscopic diagnosis 
Stage I The growth is confined to the uterus 
   Group 1. Operation advisable 
   Group 2. Bad operative risks 
Stage II The growth has spread outside the uterus 
 
 
1962-71 2nd FIGO staging for endometrial cancer--Clinical 
Stage 0 Histological findings suspicious of malignancy but not proven. 
Stage I The carcinoma is confined to the corpus. 
Stage II The carcinoma has involved the corpus and cervix. 
Stage III The carcinoma has extended outside the uterus but not outside the true pelvis. 
Stage IV The carcinoma has extended outside the true pelvis or has obviously involved the 
mucosa of the bladder or rectum 
 
 
1971-88 3rd FIGO staging for endometrial cancer--Clinical 
Stage 0 Carcinoma in-situ. Histological findings suspicious of malignancy. 
Stage I 
   Ia 
   Ib 
The carcinoma is confined to the corpus. 
The length of the uterine cavity is 8 cm. or less. 
The length of the uterine cavity is greater than 8 cm. 
Stage II The carcinoma has involved the corpus and cervix. 
Stage III The carcinoma has extended outside the uterus but not outside the true pelvis. 
Stage IV The carcinoma has extended outside the true pelvis or has obviously involved the 
mucosa of the bladder or rectum 
 It is desirable that Stage I cases be sub grouped with regard to the histological 
type of the adenocarcinoma as follows:  
G1. Highly differentiated adenomatous carcinoma 
G2. Differentiated adenomatous carcinoma with partly solid area. 
G3. Predominantly solid or entirely undifferentiated carcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1988–2009 4th FIGO staging for endometrial cancer-- Surgical 
Stage I 
   IA 
   IB 
   IC 
Tumour limited to the uterus. 
Tumour limited to the endometrium. 
Invasion <50% of the myometrium 
Invasion ≥50% of the myometrium 
Stage II 
   IIA 
   IIB 
Extension to the cervix but not beyond the uterus.  
Endocervical glandular involvement only.  
Cervical stromal invasion.  
Stage III 
   IIIA 
   IIIB 
   IIIC 
Extension outside of the uterus/cervix with/without regional metastasis. 
Tumour invades serosa or adnexa or positive peritoneal cytology. 
Vaginal metastasis. 
Metastasis to pelvic and/or paraaortic lymph nodes 
Stage IV The carcinoma has extended outside the true pelvis or has obviously involved 
the mucosa of the bladder or rectum 
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9.2 SUMMARY OF INFLUENTIAL CLINICAL STUDIES AND TRIALS IN EC 
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